MIMOTOPES OF HYPERVARIABLE REGION 1 OF THE

E2 GLYCOPROTEIN OF HCV AND USES THEREOF

The present invention is concerned with peptides, specifically

5   peptides which are mimotopes of the hypervariable region 1

(HVR1) of the putative envelope protein E2 of hepatitis C

virus (HCV). Employing a combination of techniques the

present inventors have devised a large number of peptides with

sequences based on consensus analysis of naturally occurring

10   HVR1 sequences and experimental determination of cross-

reactivity to antibodies against different isolates, none of

which peptides occurs in nature. The peptides are

individually useful in raising and obtaining antibodies, for

in vitro (e.g. diagnostic) and in vivo purposes, and libraries

15   of peptides are useful in identifying peptides of particular

cross-reactivity with antibodies able to bind a plurality of

HVR1's of different HCV strains. Peptides may be used in

themselves or as part of fusion proteins, for instance in

recombinant HCV E2 polypeptides, which may be incorporated

20   into recombinant HCV particles.

The HVR1 region of HCV is the most variable antigenic fragment

in the whole viral genome and is mainly responsible of the

large inter and intra-individual heterogeneity of the

25   infecting virus. It contains a principal neutralization

epitope and has been proposed as the major player in the

1

mechanism of escape from host immune response. Since anti-HVR1 antibodies are the only species shown to possess protective activity up to date, the development of an efficient prevention therapy is a very difficult task.

In devising the present invention, the inventors approached the problem of the HVR1 variability by deriving a consensus profile from more than two hundred HVR1 sequences from different viral isolates and used this consensus as a template for generating a vast repertoire of synthetic HVR1 surrogates. These were provided as fusions to the major coat protein VIII of M13 bacteriophage for display on the surface of bacteriophage particles. This library was affinity selected using many different sera from infected patients. Phage were identified which displayed high frequency of reactivity with patients' sera, but not with sera from uninfected controls. The selected sequences were shown to bind serum antibodies cross-reacting with a large panel of peptides reproducing the HVR1 from natural HCV variants.

In these "mimotopes" was identified a sequence pattern responsible for the observed cross-reactivity. When injected in experimental animals, the mimotopes with the highest cross-reactivity induced antibodies able to recognise the same panel of natural HVR1 variants.

Hepatitis C virus (HCV) is the major etiologic agent of both blood-transfusion-associated and sporadic non-A non-B hepatitis worldwide, with an estimated prevalence between 0.4 and 2% in the blood donor population (Choo et al., 1989). HCV

5 infection leads to viral persistence and chronic disease in at least 70% of cases, among which a significant proportion eventually develops cirrhosis and hepatocellular carcinoma (for a review see H. Alter, 1995). In spite of the availability of reliable serological tests for HCV diagnosis,

10 community-acquired infection is still common and causes significant morbidity and mortality worldwide (Mast and Alter, 1993). In addition, interferon treatment, which is the only anti-viral therapy available at the moment, is effective only in 20-30% of patients (Fried and Hoofnagle, 1995). Thus,

15 development of an HCV vaccine represents a high priority project in the field.

The high frequency with which the virus establishes a persistent infection, despite a wide array of humoral and

20 cell-mediated host immune responses, raised in the past some concerns about the existence of a protective immunity against HCV (Farci et al., 1992). As a matter of fact, protective immunity against challenge with homologous virus could be induced by vaccination of chimpanzees (the only other species

25 susceptible to HCV infection) using recombinant forms of the putative envelope proteins E1 and E2 (Choo et al., 1994).

3

However, it remains to be established how effective this response would be against heterologous viral inocula.

HCV exists in the bloodstream of infected patients as a quasispecies (Weiner et al., 1991; Martell et al., 1992; Martell et al., 1994; Kurosaki et al., 1994; Bukh et al., 1995) which fluctuates during the course of the disease mainly as a result of immune pressure (Weiner et al., 1992; Kato et al., 1993; Kojima et al., 1994; Shimizu et al., 1994; van Doorn et al., 1995; Weiner et al., 1995). The emerging view is that chronic infection by HCV is not due to lack of humoral or cellular responses, but rather to such responses being rendered ineffective by the high mutation rate of the virus which leads to the emergence of escape variants.

The existence of neutralising antibodies and their role in protection from viral infection was documented by *ex vivo* neutralization of a pedigreed viral inoculum prior to injection into chimpanzees (Farci et al., 1994). This notwithstanding, neutralising antibodies were isolate-specific and seemed to be able to block only viral variants which were present before the onset of the corresponding humoral response (Farci et al., 1994). Even if the specificity of such neutralising antibodies is not well defined, both immunological and molecular evidence indicate that epitopes recognised by neutralising antibodies are localised in the

4

hypervariable region 1 (HVR1) of the HCV genome (Farci et al.,

1994). This consists of the N-terminal 27 amino acids of the

E2 glycoprotein, the most variable region of the whole HCV

polyprotein (Weiner et al., 1991). Direct proof for the role

5   of anti-HVR1 antibodies in virus clearance came recently from

ex vivo neutralization experiments. A rabbit anti-HVR1

hyperimmune serum raised against the predominant variant of an

infectious HCV inoculum abolished its infectivity in one

chimp, and partially protected a second animal by blocking

10   propagation of the major variant present in the inoculum

(Farci et al., 1996).

Thus, the evidence is that the HVR1 contains a principal

neutralization determinant for HCV, and that it should

15   constitute an essential component of an acellular HCV vaccine

if one could surmount the problem of its variability.

Relevant to this issue is the observation that anti-HVR1

antibodies from human sera display some degree of cross-

reactivity to different HVR1 variants (Scarselli et al.,

20   1995).

WO94/26306 (Chiron Corporation) discloses an attempt at

identifying a consensus sequence within the HVR1 of HCV, based

on sequence comparison on the 90 strains said to have been

25   known as of 12 May 1993. The disclosed formula is of a

peptide including the following sequence: aa1-aa2-aa3-aa4-aa5-

5

aa6 (SEQ ID NO: 198), wherein aa1 is S, G, A, D, K , R or T;

aa2 is L, F, I, M or W; aa3 is F or L; aa4 is any amino acid;

aa5 is any amino acid; and aa6 is G or A; with the proviso

that the motif is not contained within a 31 amino acid

5   sequence of a naturally occurring E2HV domain of an HCV

isolate known as of May 12, 1993. In a further embodiment,

aa7 is present and attached to aa6 (SEQ ID NO: 199); aa7 being

A, P or S. The 6 amino acid motif represents around 55,000

different sequence. The 7 amino acid motif represents around

10   165,000 different sequences.

Aspects of the present invention are based in part on a close

inspection of the variability in HVR1 revealing that some

positions of the HVR1 are less variable than others,

15   suggesting that the actual structural, and immunological

variability is more limited than that suggested by the

heterogeneity in primary sequence. The invention is concerned

in various aspects with providing "synthetic variants" of the

HCV HVR1 which are immunologically similar to a plurality,

20   preferably a great number of natural HVR1 variants and,

therefore, may be used to induce neutralising antibodies which

cross-react with different HCV variants, preferably most or

all. As explained further below, the formulae arrived at for

peptides of the present invention differs from that provided

25   in WO94/26306, and is based on actual cross-reactivity scoring

rather than just sequence comparison.

Phage displayed peptide libraries offer the unique chance to
rapidly survey large collections of peptidic sequences (10^8 or
more) through a cyclic selection/rescue/amplification

5   procedure. They allow identification of ligands for any type
of ligate ranging from linear peptides to folded protein
domains, and even carbohydrates (Cortese et al., 1994, Cortese
et al., 1996). These ligands are true mimotopes as they do
not necessarily share the same amino acid sequence of the

10   original epitope, but they mimic its binding properties. A
strategy for the identification of disease-specific phage-
displayed mimotopes was reported previously, which avails
itself only of clinically characterized sera from immune and
non immune individuals (Folgori et al., 1994, hereby

15   incorporated by reference). Furthermore, disease-specific
mimotopes proved to be good immunogenic mimics of the natural
antigen as they were able to induce a specific immune response
to the natural antigen when injected into different animals
(Folgori et al., 1994, and Meola et al., 1995, (both hereby

20   incorporated by reference) Prezzi et al., 1996, Mecchia et
al., 1996). Thus, phage libraries may be used as a source of
artificial ligands recognised by disease-specific antibodies,
with the advantage that additional desirable features can be
built-in, providing that they can be selected for during

25   library enrichment.

In making the present invention, the inventors approached the problem of the HVR1 variability by generating a vast repertoire of HVR1 surrogates as fusion to the major coat protein (pVIII) of bacteriophage M13. Using the power of

5 selection and many sera from clinically characterized HCV infected individuals peptides were isolated which revealed to be good antigenic and immunogenic mimics of a large number of naturally occurring HCV variants.

10 Experimental details are provided below.

In accordance with various aspects of the present invention there are provided libraries of peptides containing large numbers of different peptides, individual peptides which

15 contain epitopes cross-reactive with a plurality of HCV HVR1 epitopes, and mixtures of different such peptides.

One aspect of the present invention provides a library of peptide conforming with the following consensus profile (SEQ

20 ID NO: 1):

```
Q T H V T G G S A A R T T S G L T S L F S P G A S Q N
T   T T V     V Q G H A A H S     V G     R L     P K     K
    R         Q V S Q V R R       R         S     S Q
                                                   Q
```

25 This profile represents a total of 9 x 10^7 individual sequences, i.e. a number very close to the upper practical

8

limit (about 10^8) of current DNA cloning and transformation

techniques. As described below, this consensus profile was

used for the construction of a 27aa peptide library by cloning

a degenerated synthetic oligonucleotide as a fusion to the 5'

5 end of the gene coding for the major coat protein (pVIII) in a

phagemid vector for M13. The library was extensively screened

using human sera, and more than one hundred different clones

(mimotopes) were selected for their characteristic to

specifically recognise human anti HCV-HVR1 antibodies. Nearly

10 all these mimotopes have different amino acid sequences and

none of them could be found to correspond to published (up to

January 98) natural HVR1.

In a preferred embodiment of a peptide library according to

15 the present invention there are at least about 10^5 different

peptides present, preferably at least about 10^6 different

peptides, more preferably at least about 10^7, e.g. about 9 x

10^7 different peptides.

20 A library of peptides may be displayed on the surface of

bacteriophage, particularly filamentous bacteriophage such as

fd or M13, for instance as fusions with the major coat protein

(pVIII) of such bacteriophage. Phage display of peptides is

standard in the art and its power lies in the fact that

25 bacteriophage particles are constructed so that packaged

within each particle is nucleic acid encoding the peptide

displayed on its surface. Following selection of phage particles displaying a peptide of interest, such as a peptide able to bind one or more antibodies (e.g. antibodies able to bind a number of epitopes of HVR1 of different strains of HCV), the nucleic acid encoding the displayed peptide can be retrieved and used in production of further peptide with that amino acid sequence.

In the experimental work described below, the inventors tested mimotopes in a library according to the present invention with a panel of human sera, and individual mimotopes were characterised as having a different overall frequency of reactivity with the sera. The 24 clones that only reacted with less than 3 sera were defined as "weak" while the 27 reacting with more than 11 sera were defined as "strong".

Statistical analysis of the consensus sequences of "strong" and "weak" clones, lead to the discovery of a sequence motif in the HVR1 that is correlated with high frequency of reaction with human sera, crossreactivity with human anti HVR1 antibodies and induction of highly crossreactive sera in experimental animals.

Peptides according to the present invention, and mixtures thereof, may be defined as follows, further explanation of which is given below in the experimental section:

(1) - A library of peptides fully described by the following formula ("Formula I"; SEQ ID NO: 1):

```
5   Q T H V T G G S A A R T T S G L T S L F S P G A S Q N
    T   T T V     V Q G H A A H S   V G     R L   P K   K
        R         Q V S Q V R R     R       S   S Q
                                              Q
```

which may be written as

10

(aa1)T(aa3)(aa4)(aa5)GG(aa8)(aa9)(aa10)(aa11)(aa12)(aa13)

(aa14)(aa15)L(aa17)(aa18)LF(aa21)(aa22)G(aa24)(aa25)Q(aa27)

wherein aa1 is Q or T; aa3 is H, T or R; aa4 is V or T; aa5 is

T or V; aa8 is S, V or Q;aa9 is A, Q or V; aa10 is A, G or S;

15 aa11 is R or H; aa12 is T, A or Q; aa13 is T, A or V; aa14 is

S, H or R; aa15 is G, S or R; aa17 is T or V; aa18 is S, G or

R; aa21 is S or R; aa22 is P, L, S or Q; aa24 is A, P or S;

aa25 is S, K or Q; aa27 is N or K..

20 (2) - 27 "strong" peptides obtainable from such a library are

preferred peptides according to various aspects of the present

invention, having an amino acid sequence as follows:

2.11 QT H TVGGVQG R QAHSLT S LF S P G A SQN (SEQ ID NO: 2)

25 D6   QT T TTGGQVS H ATHGLT G LF S L G P QQK (SEQ ID NO: 3)

D18 QT H TTGGSAS H QASGLT R LF S Q G P SQN (SEQ ID NO: 4)

·11

```
F63    QT H VVGGQQG R QVSSLV S LF S P G A SQK (SEQ ID NO: 5)

G31    TT H TVGGSVA R QVHSLT G LF S P G P QQK (SEQ ID NO: 6)

L13    QT H TVGGSQA H AAHSLT R LF S P G S SQN (SEQ ID NO: 7)

M69    QT T VVGGSQA R AAHGLV S LF S L G S KQN (SEQ ID NO: 8)

5   Z61    QT H VVGGVQG R QTSGLV G LF S P G S KQN (SEQ ID NO: 9)

R9     QT T VVGGSQS H TVRGLT S LF S P G A SQN (SEQ ID NO: 10)

B26    TT T TTGGQAG H QAHSLT S LF S P G A SQK (SEQ ID NO: 11)

B22    QT H VVGGVQS H QTSGLT S LF S P G A SQK (SEQ ID NO: 12)

B35    QT H TTGGVQG H QTSRLT S LF S P G P SQN (SEQ ID NO: 13)

10  D29    TT T VVGGQAA H QTHSLT S LF S P G A KQN (SEQ ID NO: 14)

D33    TT T TTGGQQS H TVHGLV G LF S P G S KQN (SEQ ID NO: 15)

E26    QT H TVGGVQA H TVRGLT S LF S P G S SQN (SEQ ID NO: 16)

F80    QT H TTGGQAG H TASSLT G LF S P G A KQN (SEQ ID NO: 17)

F19    QT T TVGGVAS H QAHSLT G LF S P G A KQK (SEQ ID NO: 18)

15  F78    QT H TTGGQAG H QAHSLT G LF S P G A KQN (SEQ ID NO: 19)

H1     QT H TTGGVVG H ATSGLT S LF S P G P SQK (SEQ ID NO: 20)

L76    TT T TVGGQAS H QTSSLT G LF S P G S KQN (SEQ ID NO: 21)

M27    QT T TTGGVAS H AAHRLT S LF S P G P QQK (SEQ ID NO: 22)

M122 QT T TTGGSAS H AVSSLT G LF S P G S KQN (SEQ ID NO: 23)

20  M129 QT T VVGGSAG H TASSLV G LF S P G S KQN (SEQ ID NO: 24)

M119 TT T TVGGQAS H TTSSLT G LF S P G S QQN (SEQ ID NO: 25)

R5     QT H TTGGQAS H QVSSLV S LF S P G A KQK (SEQ ID NO: 26)

R6     TT T TTGGQVG H QTSGLT G LF S P G A QQN (SEQ ID NO: 27)

R27    TT H VVGGSAS H AVRGLT S LF S P G S SQN (SEQ ID NO: 28)

25
```

Further preferred peptides according to the present invention
have any of the following sequences:

```
     B14   QT T VTG_QAS H TTSSLT G LF S P G A SQK   (SEQ ID NO: 29)

 5   B33   aT H aTGGQAA H STHSLT S LF S P G A SQK   (SEQ ID NO: 30)

     F81   QT H VTGGSAA H QTgGLT G LF S P G P KQN   (SEQ ID NO: 31)

     B18   QT T VVGGQAS H _VSRLT G LF S P G S SQK   (SEQ ID NO: 32)

     L72   QT T T____AA H TTSGLT G LF S P G A KQN   (SEQ ID NO: 33)

     D20   QT H VTG_VAG R QTSGLV S LF S P G S SQN   (SEQ ID NO: 34)

10   D30   Q_ _ __GGVQG H TTSSLV G LF S P G S QQN   (SEQ ID NO: 35)

     E19   TT H T_GGQQA H TTSRLV S LF S P G A SQK   (SEQ ID NO: 36)

     B24   TT T TVGGQAS H TTSSLT G LF S P G A SQK   (SEQ ID NO: 37)

     M63   QT H TTGGVVS H QTRSLV G LF S P G P QQN   (SEQ ID NO: 38)
```

15   The lower case letters are used to identify amino acid
residues that vary from Formula 1, while the underlined spaces
are included to signify deletions compared with Formula 1,
though the flanking amino acids are of course contiguous in
the relevant peptides.

20

These are variants of peptides obtainable from a library in
accordance with the present invention, not themselves
conforming with Formula I. They were identified in the course
of the experiments identified below and originated by PCR
25   errors during library amplification. (See Materials and
Methods, "Construction of the HVR1 library".)

13

(3) - A "strong consensus" ("Formula II"), derived from the consensus of the highly cross-reactive peptides of (2) above.

The statistical analysis of the frequencies of aa in any position in the 27 "strong" in comparison with the frequency in 25 "weak" is shown in Table II, and discussed further below in the experimental section.

Formula II (SEQ ID NO: 39):

QT(aa3)TV**GG**QQS(aa11)QVHS**LT**(aa18)**LF**(aa21)(aa22)**G**(aa24)SQN

where: aa3 is H or T; aa11 is H or R; aa18 is G, S or R; aa21 is S; aa22 is P, L or Q; aa24 is A, S or P;

which may also be written:

QT	**H**	TVGGQAS	**H**	QASSLT	**S**	LF	**S**	**P**	G	**A**	KQN
	T		R		**G**		L	**S**			
			R				Q	**P**			

Residues in italics are included because although they have low frequencies they are found in some of the best reactive mimotopes tested (highlighted with an asterisk among the 27 "strong" peptides at II above.

14

The 27 mimotopes used to derive Formula II are not in it.

108 peptides conform to Formula II and each is an aspect of
the invention.   The sequences are:

5

    1 QTHTV GGQAS HQASS LTSLF SPGAK QN (SEQ ID NO: 40)

    2 QTHTV GGQAS HQASS LTSLF SPGSK QN (SEQ ID NO: 41)

    3 QTHTV GGQAS HQASS LTSLF SPGPK QN (SEQ ID NO: 42)

    4 QTHTV GGQAS HQASS LTSLF SLGAK QN (SEQ ID NO: 43)

10 5 QTHTV GGQAS HQASS LTSLF SLGSK QN (SEQ ID NO: 44)

    6 QTHTV GGQAS HQASS LTSLF SLGPK QN (SEQ ID NO: 45)

    7 QTHTV GGQAS HQASS LTSLF SQGAK QN (SEQ ID NO: 46)

    8 QTHTV GGQAS HQASS LTSLF SQGSK QN (SEQ ID NO: 47)

    9 QTHTV GGQAS HQASS LTSLF SQGPK QN (SEQ ID NO: 48)

15 10 QTHTV GGQAS HQASS LTGLF SPGAK QN (SEQ ID NO: 49)

   11 QTHTV GGQAS HQASS LTGLF SPGSK QN (SEQ ID NO: 50)

   12 QTHTV GGQAS HQASS LTGLF SPGPK QN (SEQ ID NO: 51)

   13 QTHTV GGQAS HQASS LTGLF SLGAK QN (SEQ ID NO: 52)

   14 QTHTV GGQAS HQASS LTGLF SLGSK QN (SEQ ID NO: 53)

20 15 QTHTV GGQAS HQASS LTGLF SLGPK QN (SEQ ID NO: 54)

   16 QTHTV GGQAS HQASS LTGLF SQGAK QN (SEQ ID NO: 55)

   17 QTHTV GGQAS HQASS LTGLF SQGSK QN (SEQ ID NO: 56)

   18 QTHTV GGQAS HQASS LTGLF SQGPK QN (SEQ ID NO: 57)

   19 QTHTV GGQAS HQASS LTRLF SPGAK QN (SEQ ID NO: 58)

25 20 QTHTV GGQAS HQASS LTRLF SPGSK QN (SEQ ID NO: 59)

   21 QTHTV GGQAS HQASS LTRLF SPGPK QN (SEQ ID NO: 60)

15

22 QTHTV GGQAS HQASS LTRLF SLGAK QN (SEQ ID NO: 61)

23 QTHTV GGQAS HQASS LTRLF SLGSK QN (SEQ ID NO: 62)

24 QTHTV GGQAS HQASS LTRLF SLGPK QN (SEQ ID NO: 63)

25 QTHTV GGQAS HQASS LTRLF SQGAK QN (SEQ ID NO: 64)

5   26 QTHTV GGQAS HQASS LTRLF SQGSK QN (SEQ ID NO: 65)

27 QTHTV GGQAS HQASS LTRLF SQGPK QN (SEQ ID NO: 66)

28 QTHTV GGQAS RQASS LTSLF SPGAK QN (SEQ ID NO: 67)

29 QTHTV GGQAS RQASS LTSLF SPGSK QN (SEQ ID NO: 68)

30 QTHTV GGQAS RQASS LTSLF SPGPK QN (SEQ ID NO: 69)

10 31 QTHTV GGQAS RQASS LTSLF SLGAK QN (SEQ ID NO: 70)

32 QTHTV GGQAS RQASS LTSLF SLGSK QN (SEQ ID NO: 71)

33 QTHTV GGQAS RQASS LTSLF SLGPK QN (SEQ ID NO: 72)

34 QTHTV GGQAS RQASS LTSLF SQGAK QN (SEQ ID NO: 73)

35 QTHTV GGQAS RQASS LTSLF SQGSK QN (SEQ ID NO: 74)

15 36 QTHTV GGQAS RQASS LTSLF SQGPK QN (SEQ ID NO: 75)

37 QTHTV GGQAS RQASS LTGLF SPGAK QN (SEQ ID NO: 76)

38 QTHTV GGQAS RQASS LTGLF SPGSK QN (SEQ ID NO: 77)

39 QTHTV GGQAS RQASS LTGLF SPGPK QN (SEQ ID NO: 78)

40 QTHTV GGQAS RQASS LTGLF SLGAK QN (SEQ ID NO: 79)

20 41 QTHTV GGQAS RQASS LTGLF SLGSK QN (SEQ ID NO: 80)

42 QTHTV GGQAS RQASS LTGLF SLGPK QN (SEQ ID NO: 81)

43 QTHTV GGQAS RQASS LTGLF SQGAK QN (SEQ ID NO: 82)

44 QTHTV GGQAS RQASS LTGLF SQGSK QN (SEQ ID NO: 83)

45 QTHTV GGQAS RQASS LTGLF SQGPK QN (SEQ ID NO: 84)

25 46 QTHTV GGQAS RQASS LTRLF SPGAK QN (SEQ ID NO: 85)

47 QTHTV GGQAS RQASS LTRLF SPGSK QN (SEQ ID NO: 86)

16

48 QTHTV GGQAS RQASS LTRLF SPGPK QN (SEQ ID NO: 87)

49 QTHTV GGQAS RQASS LTRLF SLGAK QN (SEQ ID NO: 88)

50 QTHTV GGQAS RQASS LTRLF SLGSK QN (SEQ ID NO: 89)

51 QTHTV GGQAS RQASS LTRLF SLGPK QN (SEQ ID NO: 90)

5   52 QTHTV GGQAS RQASS LTRLF SQGAK QN (SEQ ID NO: 91)

53 QTHTV GGQAS RQASS LTRLF SQGSK QN (SEQ ID NO: 92)

54 QTHTV GGQAS RQASS LTRLF SQGPK QN (SEQ ID NO: 93)

55 QTTTV GGQAS HQASS LTSLF SPGAK QN (SEQ ID NO: 94)

56 QTTTV GGQAS HQASS LTSLF SPGSK QN (SEQ ID NO: 95)

10 57 QTTTV GGQAS HQASS LTSLF SPGPK QN (SEQ ID NO: 96)

58 QTTTV GGQAS HQASS LTSLF SLGAK QN (SEQ ID NO: 97)

59 QTTTV GGQAS HQASS LTSLF SLGSK QN (SEQ ID NO: 98)

60 QTTTV GGQAS HQASS LTSLF SLGPK QN (SEQ ID NO: 99)

61 QTTTV GGQAS HQASS LTSLF SQGAK QN (SEQ ID NO: 100)

15 62 QTTTV GGQAS HQASS LTSLF SQGSK QN (SEQ ID NO: 101)

63 QTTTV GGQAS HQASS LTSLF SQGPK QN (SEQ ID NO: 102)

64 QTTTV GGQAS HQASS LTGLF SPGAK QN (SEQ ID NO: 103)

65 QTTTV GGQAS HQASS LTGLF SPGSK QN (SEQ ID NO: 104)

66 QTTTV GGQAS HQASS LTGLF SPGPK QN (SEQ ID NO: 105)

20 67 QTTTV GGQAS HQASS LTGLF SLGAK QN (SEQ ID NO: 106)

68 QTTTV GGQAS HQASS LTGLF SLGSK QN (SEQ ID NO: 107)

69 QTTTV GGQAS HQASS LTGLF SLGPK QN (SEQ ID NO: 108)

70 QTTTV GGQAS HQASS LTGLF SQGAK QN (SEQ ID NO: 109)

71 QTTTV GGQAS HQASS LTGLF SQGSK QN (SEQ ID NO: 110)

25 72 QTTTV GGQAS HQASS LTGLF SQGPK QN (SEQ ID NO: 111)

73 QTTTV GGQAS HQASS LTRLF SPGAK QN (SEQ ID NO: 112)

17

74 QTTTV GGQAS HQASS LTRLF SPGSK QN (SEQ ID NO: 113)

75 QTTTV GGQAS HQASS LTRLF SPGPK QN (SEQ ID NO: 114)

76 QTTTV GGQAS HQASS LTRLF SLGAK QN (SEQ ID NO: 115)

77 QTTTV GGQAS HQASS LTRLF SLGSK QN (SEQ ID NO: 116)

78 QTTTV GGQAS HQASS LTRLF SLGPK QN (SEQ ID NO: 117)

79 QTTTV GGQAS HQASS LTRLF SQGAK QN (SEQ ID NO: 118)

80 QTTTV GGQAS HQASS LTRLF SQGSK QN (SEQ ID NO: 119)

81 QTTTV GGQAS HQASS LTRLF SQGPK QN (SEQ ID NO: 120)

82 QTTTV GGQAS RQASS LTSLF SPGAK QN (SEQ ID NO: 121)

83 QTTTV GGQAS RQASS LTSLF SPGSK QN (SEQ ID NO: 122)

84 QTTTV GGQAS RQASS LTSLF SPGPK QN (SEQ ID NO: 123)

85 QTTTV GGQAS RQASS LTSLF SLGAK QN (SEQ ID NO: 124)

86 QTTTV GGQAS RQASS LTSLF SLGSK QN (SEQ ID NO: 125)

87 QTTTV GGQAS RQASS LTSLF SLGPK QN (SEQ ID NO: 126)

88 QTTTV GGQAS RQASS LTSLF SQGAK QN (SEQ ID NO: 127)

89 QTTTV GGQAS RQASS LTSLF SQGSK QN (SEQ ID NO: 128)

90 QTTTV GGQAS RQASS LTSLF SQGPK QN (SEQ ID NO: 129)

91 QTTTV GGQAS RQASS LTGLF SPGAK QN (SEQ ID NO: 130)

92 QTTTV GGQAS RQASS LTGLF SPGSK QN (SEQ ID NO: 131)

93 QTTTV GGQAS RQASS LTGLF SPGPK QN (SEQ ID NO: 132)

94 QTTTV GGQAS RQASS LTGLF SLGAK QN (SEQ ID NO: 133)

95 QTTTV GGQAS RQASS LTGLF SLGSK QN (SEQ ID NO: 134)

96 QTTTV GGQAS RQASS LTGLF SLGPK QN (SEQ ID NO: 135)

97 QTTTV GGQAS RQASS LTGLF SQGAK QN (SEQ ID NO: 136)

98 QTTTV GGQAS RQASS LTGLF SQGSK QN (SEQ ID NO: 137)

99 QTTTV GGQAS RQASS LTGLF SQGPK QN (SEQ ID NO: 138)

18

100 QTTTV GGQAS RQASS LTRLF SPGAK QN (SEQ ID NO: 139)

101 QTTTV GGQAS RQASS LTRLF SPGSK QN (SEQ ID NO: 140)

102 QTTTV GGQAS RQASS LTRLF SPGPK QN (SEQ ID NO: 141)

103 QTTTV GGQAS RQASS LTRLF SLGAK QN (SEQ ID NO: 142)

104 QTTTV GGQAS RQASS LTRLF SLGSK QN (SEQ ID NO: 143)

105 QTTTV GGQAS RQASS LTRLF SLGPK QN (SEQ ID NO: 144)

106 QTTTV GGQAS RQASS LTRLF SQGAK QN (SEQ ID NO: 145)

107 QTTTV GGQAS RQASS LTRLF SQGSK QN (SEQ ID NO: 146)

108 QTTTV GGQAS RQASS LTRLF SQGPK QN (SEQ ID NO: 147)

(4) - A further library of peptides within the library of Formula I, including the sequences of Formula II, defining 2.5 x 10^6 sequences and conforming to the following Formula III (SEQ ID NO: 148):

```
Q T H T V G G Q A S H Q A S S L T S L F S P G A K Q N
  T   T V T     S Q G   A T H G   V G       S S   K
            V V A   T V R R             P Q
```

A peptide according to the present invention may be provided in a fusion with additional amino acids. Additional amino acids may be fused at one or both of the N-terminus and the C-terminus of the peptide. The additional amino acids may be an amino acid sequence that is not a fragment of HCV E2 protein, or may be an amino acid sequence that is part of that protein. Furthermore, a fusion including a peptide according to the

19

present invention may include a HCV E2/NS1 protein with the

peptide amino acid sequence in the HVR1 position, i.e. such

that the mimotope HVR1 peptide of the invention substitutes

for the natural HVR1 sequence. Another way of expressing this

5   is to refer to a "recombinant HCV E2/NS1 protein in which a

peptide of the present invention is substituted for the HVR1".

As noted below, nucleic acid encoding peptides and

polypeptides, including fusions, according to invention are

provided as further aspects of the invention, as is a

10   recombinant HCV genome including a nucleotide sequence

encoding a peptide of the invention, for instance within the

E2/NS1 coding sequence to provide for production of a

recombinant HCV E2/NS1 protein in which a peptide of the

invention is substituted for the HVR1 and incorporation of the

15   recombinant protein into an assembled HCV particle. A

recombinant HCV particle including one or more peptides or

polypeptides as disclosed herein is provided as a further

aspect of the present invention.

20   Generally, a peptide according to the present invention is

immunogenic or able to raise an immune response on

administration to an individual or includes an epitope

immunologically cross-reactive with an epitope of a plurality

of strains of HCV.

25

Another aspect of the present invention provides a method of

obtaining one or more peptides containing an epitope

immunologically cross-reactive with an epitope in the HVR1 of

an HCV strain, the method including bringing into contact a

5   library of peptides as disclosed and an antibody molecule able

to bind said HVR1 of an HCV strain, and selecting one or more

peptides of the library able to bind said antibody molecule.

The peptide or peptides selected may contain an epitope

10   immunologically cross-reactive with the HVR1 of a plurality of

strains of HCV.

Such a method may include bringing into contact a library of

peptides and a plurality of antibody molecules collectively

15   able to bind the HVR1 of a plurality of strains of HCV. In

one embodiment, said plurality of antibody molecules is

derived from sera of individuals infected with HCV.

As noted, said library may be displayed on the surface of

20   bacteriophage particles, each particle containing nucleic acid

encoding the peptide displayed on its surface. Following

selection, nucleic acid may be taken from a bacteriophage

particle displaying a said selected peptide. Nucleic acid

with the sequence of nucleic acid taken from a bacteriophage

25   particle displaying a said selected peptide may be used in

production of such a peptide by means of expression (using

recombinant DNA technology as standard in the art and
discussed further below).

A peptide with the amino acid sequence of a said selected

5   peptide may provided in isolated form, e.g. after its
production by expression from encoding nucleic acid. As noted
further below, one or more peptides in accordance with the
present invention may be provided by peptide synthesis.

10   A plurality of peptides each with the amino acid sequence of a
different selected peptide may provided in isolated form,
individually or in a mixture.

A selected peptide or selected peptides may each have an amino

15   acid sequence according to the Formula II given above. All
108 of the different peptides according to Formula II may be
provided as a mixture, and furthermore each individually
represents an aspect of the present invention. Each peptide
of these 108 has a high probability of being cross-reactive

20   with epitopes in the HVR1 of the E2/NS2 protein of a number of
strains of HCV, and therefore is particularly useful for
obtaining antibodies or otherwise raising an immune response.

A composition according to the present invention may include a

25   plurality of peptides obtainable from a mixture of the 108
peptides of Formula II. Such a composition may include from 2

22

to about 20, 15, 10, 9, 8, 7, 6, 5, 4 or 3 different peptides

obtainable from said mixture.

Preferred peptides which may be provided in a mixture or

5   individually include those denoted G31, F78, R9, D6, M122 and

H1 of which the amino acid sequences are shown in Figure 7(A).

Preferred mixtures included peptides R9, F78, H1 and D6

("MIX1"), include peptides M122 and G31 ("MIX2"), or include

peptides G31, F78, R9, D6, M122 and H1 ("MIX3").

10

Immunological cross-reactivity of each peptide of the

invention with the HVR1 of HCV strains can be assessed

experimentally, as exemplified below. Various mixtures of

these peptides may also be made and similarly tested, again as

15   experimentally exemplified below.

Linear or branched (e.g. MAP) peptides and polypeptides (e.g.

fusion molecules including a peptide as discussed) in

accordance with the present invention may be made using any of

20   a variety of techniques at the disposal of the ordinary person

skilled in the art.

Linear or branched peptides may be synthesized using standard

peptide chemistry such as by the common method employing Fmoc

25   (Fluorenilmetil-ossicarbonil)t-Bu (*tert*-butil), as described

in Atherton and Sheppard (1989), *Solid Phase Peptide*

23

Synthesis, a Practical Approach, IRL Press, Oxford.

A convenient way of producing a peptide or polypeptide according to the present invention is to express nucleic acid

5   encoding it, by use of the nucleic acid in an expression system.

Accordingly, the present invention also encompasses a method of making a peptide or polypeptide (as disclosed), the method

10   including expression from nucleic acid encoding the peptide or polypeptide (generally nucleic acid according to the invention). This may conveniently be achieved by growing a host cell in culture, containing such a vector, under appropriate conditions which cause or allow expression of the

15   polypeptide. Peptides and polypeptides may also be expressed in *in vitro* systems, such as reticulocyte lysate.

Polynucleotides encoding peptides and polypeptides according to the present invention represent further aspects of the

20   invention.

In one aspect there is provided a polynucleotide encoding a peptide as disclosed. In a further aspect, there is provided a polynucleotide encoding a fusion as disclosed, particularly

25   a HCV E2/NS1 protein including the amino acid sequence of a peptide of the invention in the HVR1 position. In a further

24

aspect, there is provided a recombinant HCV genome including a nucleotide sequence encoding a peptide according to the invention or a fusion as disclosed, particularly a HCV E2/NS1 protein with the relevant peptide amino acid sequence in the

5 HVR1 position.

In a still further aspect, a polynucleotide is provided which includes a plurality of nucleotide sequences encoding peptides or polypeptides according to the invention. This allows for

10 production of a mixture of peptides or polypeptides in a single expression reaction.

Nucleic acid encoding a peptide or polypeptide according to the present invention may be used in nucleic acid immunisation

15 in order to raise an immune response in a mammal, such as a human individual for a therapeutic or prophylactic purpose, or a non-human mammal for such a purpose or in order to produce antibodies for subsequent manipulation and/or use (e.g. in diagnostic or therapeutic contexts as discussed further

20 below.)

Nucleic acid encoding a peptide or polypeptide according to the present invention may be used in a method of gene therapy, in prevention and/or treatment of HCV infection. This

25 requires use of suitable regulatory elements for expression and a suitable vector for deliver of the expression unit

25

(coding sequence and regulatory elements) to host cells. A variety of vectors, both viral vectors and plasmid vectors, are known in the art, see e.g. US Patent No. 5,252,479 and WO 93/07282. In particular, a number of viruses have been used

5 as gene transfer vectors, including papovaviruses, such as SV40, vaccinia virus, herpesviruses, including HSV and EBV, and retroviruses. Many gene therapy protocols in the prior art have used disabled murine retroviruses. A variety of adenovirus and adeno-associated viral vectors have been

10 developed. Alternatives to viral vectors include transfer mediated by liposomes and direct DNA uptake and receptor-mediated DNA transfer.

Host cells containing nucleic acid encoding a peptide or

15 polypeptide (or mixture thereof) according to the present invention may themselves be used in therapeutic or prophylactic treatment of individuals for or against HCV infection (i.e. therapeutic treatment of an individual with an HCV infection or prophylactic treatment of an individual prior

20 to HCV infection).

Nucleic acid is generally provided as DNA or RNA, though may include one or more nucleotide analogues, and may be wholly or partially synthetic. Nucleic acid molecules and vectors

25 according to the present invention may be provided in isolated and/or purified form, e.g. in substantially pure or

26

homogeneous form.   The term "isolate" may be used to reflect

all these possibilities.   Where a DNA sequence is specified,

e.g. with reference to a figure, unless context requires

otherwise the RNA equivalent, with U substituted for T where

5   it occurs, is encompassed.

Where it is desired to express a peptide or polypeptide from

encoding nucleic acid, the nucleic acid includes appropriate

regulatory control sequences.   Suitable vectors can be chosen

10   or constructed, containing appropriate regulatory sequences,

including promoter sequences, terminator fragments,

polyadenylation sequences, enhancer sequences, marker genes

and other sequences as appropriate.   Vectors may be plasmids,

viral e.g. 'phage, or phagemid, as appropriate.   For further

15   details see, for example, Molecular Cloning: a Laboratory

Manual: 2nd edition, Sambrook et al., 1989, Cold Spring

Harbor Laboratory Press.   Many known techniques and protocols

for manipulation of nucleic acid, for example in preparation

of nucleic acid constructs, mutagenesis, sequencing,

20   introduction of DNA into cells and gene expression, and

analysis of proteins, are described in detail in Current

Protocols in Molecular Biology, Ausubel et al. eds., John

Wiley & Sons, 1992.

25   Systems for cloning and expression of a polypeptide in a

variety of different host cells are well known.   Suitable host

27

cells include bacteria, eukaryotic cells such as mammalian and
yeast, and baculovirus systems. Mammalian cell lines
available in the art for expression of a heterologous
polypeptide include Chinese hamster ovary cells, HeLa cells,

5   baby hamster kidney cells, COS cells and many others. A
common, preferred bacterial host is *E. coli*.

A further aspect of the present invention provides a host cell
containing nucleic acid as disclosed herein. The nucleic acid

10   of the invention may be integrated into the genome (e.g.
chromosome) of the host cell. Integration may be promoted by
inclusion of sequences which promote recombination with the
genome, in accordance with standard techniques. The nucleic
acid may be on an extra-chromosomal vector within the cell.

15

A still further aspect provides a method which includes
introducing the nucleic acid into a host cell. The
introduction, which may (particularly for *in vitro*
introduction) be generally referred to without limitation as

20   "transformation", may employ any available technique. For
eukaryotic cells, suitable techniques may include calcium
phosphate transfection, DEAE-Dextran, electroporation,
liposome-mediated transfection and transduction using
retrovirus or other virus, e.g. vaccinia or, for insect cells,

25   baculovirus. For bacterial cells, suitable techniques may
include calcium chloride transformation, electroporation and

28

transfection using bacteriophage. As an alternative, direct

injection of the nucleic acid could be employed. Marker genes

such as antibiotic resistance or sensitivity genes may be used

in identifying clones containing nucleic acid of interest, as

5   is well known in the art.

The introduction may be followed by causing or allowing

expression from the nucleic acid, e.g. by culturing host cells

(which may include cells actually transformed although more

10   likely the cells will be descendants of the transformed cells)

under conditions for expression of the gene, so that the

encoded peptide or polypeptide is produced. If the peptide or

polypeptide is expressed coupled to an appropriate signal

leader peptide it may be secreted from the cell into the

15   culture medium. Following production by expression, a peptide

or polypeptide may be isolated and/or purified from the host

cell and/or culture medium, as the case may be, and

subsequently used as desired, e.g. in the formulation of a

composition which may include one or more additional

20   components, such as a pharmaceutical composition which

includes one or more pharmaceutically acceptable excipients,

vehicles or carriers (e.g. see below).

A peptide or polypeptide according to the present invention

25   may be used as an immunogen or otherwise in obtaining binding

antibodies. Antibodies are useful in purification and other

manipulation of polypeptides and peptides, diagnostic screening and therapeutic contexts, including passive immunisation. This is discussed further below.

5   According to a further aspect of the present invention there is provided a method of obtaining one or more antibody molecules containing a binding site able to bind an epitope in the HVR1 of a plurality of HCV strains, the method including bringing into contact a population of antibody molecules and a

10   peptide according to the present invention, and selecting one or more antibody molecules of the population able to bind said peptide.

The method may involve bringing the population of antibodies

15   into contact with a plurality of peptides according to the invention.

As noted, the peptides may be provided in a fusion with additional amino acids.

20

The peptide or peptides may be administered to a non-human mammal to bring them into contact with a population of antibody molecules produced by the mammal's immune system, then one or more antibody molecules able to bind the peptide

25   or peptides may be taken from the mammal, or cells producing such antibody molecules may be taken from the mammal.

30

The mammal may be sacrificed.

If cells are taken from the mammal, antibody molecules may be
5   taken from said cells or descendants thereof. Such
descendants in particular may include hybridoma cells.

Instead or as well as immunising an animal, a method of
obtaining antibodies as disclosed may involve displaying the
10   population of antibody molecules on the surface of
bacteriophage particles, each particle containing nucleic acid
encoding the antibody molecule displayed on its surface.
Nucleic acid may be taken from a bacteriophage particle
displaying an antibody molecule able to bind a peptide or
15   peptides of interest, for manipulation and/or use in
production of the encoded antibody molecule or a derivative
thereof (e.g. a fusion protein, a molecule including a
constant region or other amino acids, and so on). Instead of
using bacteriophage for display, ribosomes or polysomes may be
20   used, e.g. as disclosed in US-A-5643768, US-A-5658754,
WO95/11922.

Antibody molecules may be provided in isolated form, either
individually or in a mixture. A plurality of antibody
25   molecules may be provided in isolated form.

Preferred antibodies according to the invention are isolated, in the sense of being free from contaminants such as antibodies able to bind other polypeptides and/or free of serum components. Monoclonal antibodies are preferred for some purposes, though polyclonal antibodies are within the scope of the present invention. Indeed, polyclonal mixtures able to bind one or more peptides or polypeptides according to the present invention are preferred in some embodiments, as discussed. Thus, the present invention in a further aspect is directed to a mixture of different antibodies able to bind one or more peptides or polypeptides according to the invention. Such a mixture may be provided in a composition including at least one additional component, such as a pharmaceutically acceptable excipient or vehicle.

The present invention also extends to methods of obtaining and/or raising antibodies to one or more peptides or polypeptides of the invention. Such methods may include administering a peptide or polypeptide or mixture of peptides or polypeptides to a mammal in order to raise an antibody response. In a therapeutic or prophylactic context the mammal may be human or non-human. For the production of antibodies or antibody-producing cells to be isolated and used for any of a variety of purposes, a step of sacrificing a non-human mammal may be included. Such a non-human mammal may be for example mouse, rat, rabbit, dog, cat, pig, horse, donkey,

goat, sheep, camel, Old World monkey, chimpanzee or other primate. Antibodies may be obtained from immunised animals using any of a variety of techniques known in the art, and screened, preferably using binding of antibody to peptide or polypeptide of interest. For instance, Western blotting techniques or immunoprecipitation may be used (Armitage et al, Nature, 357:80-82, 1992).

The production of polyclonal and monoclonal antibodies is well established in the art. Monoclonal antibodies can be subjected to the techniques of recombinant DNA technology to produce other antibodies or chimeric molecules which retain the specificity of the original antibody. Such techniques may involve introducing DNA encoding the immunoglobulin variable region, or the complementarity determining regions (CDRs), of an antibody to the constant regions, or constant regions plus framework regions, of a different immunoglobulin. See, for instance, EP-A-184187, GB-A-2188638 or EP-A-239400. Humanised antibodies in which CDRs from a non-human source are grafted onto human framework regions, typically with the alteration of some of the framework amino acid residues, to provide antibodies which are less immunogenic than the parent non-human antibodies, are also included within the present invention. A hybridoma producing a monoclonal antibody according to the present invention may be subject to genetic mutation or other changes , which may or may not alter the

binding specificity of antibodies produced. Cloning and expression of chimeric antibodies are described in EP-A-0120694 and EP-A-0125023.

5   As an alternative or supplement to immunising a mammal with a peptide, an antibody specific for a protein may be obtained from a recombinantly produced library of expressed immunoglobulin variable domains, e.g. using bacteriophage which display functional immunoglobulin binding domains on

10   their surfaces - for instance see WO92/01047 - or ribosomes/polysomes as noted above. The library may be naive, that is constructed from sequences obtained from an organism which has not been immunised with any of the proteins (or fragments), or may be one constructed using sequences obtained

15   from an organism which has been exposed to the antigen of interest.

Antibodies according to the present invention may be modified in a number of ways. Indeed the term "antibody" should be

20   construed as covering any binding substance having a binding domain with the required specificity. Thus the invention covers antibody fragments, derivatives, functional equivalents and homologues of antibodies, including synthetic molecules and molecules whose shape mimics that of an antibody enabling

25   it to bind an antigen or epitope.

Example antibody fragments, capable of binding an antigen or other binding partner are the Fab fragment consisting of the VL, VH, Cl and CH1 domains; the Fd fragment consisting of the VH and CH1 domains; the Fv fragment consisting of the VL and VH domains of a single arm of an antibody; the dAb fragment which consists of a VH domain; isolated CDR regions and F(ab')2 fragments, a bivalent fragment including two Fab fragments linked by a disulphide bridge at the hinge region. Single chain Fv fragments are also included.

Hybridomas capable of producing antibody with desired binding characteristics are within the scope of the present invention, as are host cells, eukaryotic or prokaryotic, containing nucleic acid encoding antibodies (including antibody fragments) and capable of their expression. The invention also provides methods of production of the antibodies including growing a cell capable of producing the antibody under conditions in which the antibody is produced, and preferably secreted.

The reactivities of antibodies on a sample (e.g. in a diagnostic test) may be determined by any appropriate means. Tagging with individual reporter molecules is one possibility. The reporter molecules may directly or indirectly generate detectable, and preferably measurable, signals. The linkage of reporter molecules may be directly or indirectly,

35

covalently, e.g. via a peptide bond or non-covalently.
Linkage via a peptide bond may be as a result of recombinant
expression of a gene fusion encoding antibody and reporter
molecule.

5

One favoured mode is by covalent linkage of each antibody with
an individual fluorochrome, phosphor or laser dye with
spectrally isolated absorption or emission characteristics.
Suitable fluorochromes include fluorescein, rhodamine,

10   phycoerythrin and Texas Red. Suitable chromogenic dyes
include diaminobenzidine.

Other reporters include macromolecular colloidal particles or
particulate material such as latex beads that are coloured,

15   magnetic or paramagnetic, and biologically or chemically
active agents that can directly or indirectly cause detectable
signals to be visually observed, electronically detected or
otherwise recorded. These molecules may be enzymes which
catalyse reactions that develop or change colours or cause

20   changes in electrical properties, for example. They may be
molecularly excitable, such that electronic transitions
between energy states result in characteristic spectral
absorptions or emissions. They may include chemical entities
used in conjunction with biosensors. Biotin/avidin or

25   biotin/streptavidin and alkaline phosphatase detection systems
may be employed.

36

The mode of determining binding is not a feature of the present invention and those skilled in the art are able to choose a suitable mode according to their preference and general knowledge.

Antibodies according to the present invention may be used in screening for the presence of a peptide or polypeptide, for example in a test sample containing cells or cell lysate as discussed, and may be used in purifying and/or isolating a peptide or polypeptide according to the present invention, for instance following production of the polypeptide by expression from encoding nucleic acid therefor.

Antibodies are also useful in prophylaxis, by way of passive immunisation, and in therapy. Where antibodies are to be administered, it may be preferable to include a mixture of antibodies, such as antibodies collectively cross-reactive with a plurality of peptides according to the present invention.

Antibodies which bind a peptide in accordance with the present invention may themselves be used as immunogens in the production of anti-idiotypic antibodies. These may be used to mimic a peptide epitope in raising an immune response in an individual, e.g. for therapeutic and/or prophylactic purposes.

37

An antibody may be provided in a kit, which may include
instructions for use of the antibody, e.g. in determining the
presence of a particular substance in a test sample. One or
more other reagents may be included, such as labelling
molecules, buffer solutions, elutants and so on. Reagents may
be provided within containers which protect them from the
external environment, such as a sealed vial.

Diagnostic methods make use of biological samples from
individuals that may contain one or more HCV strains.
Examples of biological samples include fluid such as blood,
plasma, serum, urine and saliva, and tissue samples.

There are various methods for determining the presence or
absence in a test sample of a particular peptide or
polypeptide, including methods wherein the polypeptide to be
detected is an antibody.

A sample may be tested for the presence of a specific binding
member such as an antibody (or mixture of antibodies) directed
to one or more peptides of the invention.

Peptides according to the present invention may be used to
determine the presence or absence of antibodies against HCV
strains in test samples, by assessment of binding the peptides

38

to anti-HCV E2HVR1 antibodies if present in the sample.

In theory it may be possible to identify the presence in a sample of a binding partner for a specific binding member such as an antibody (or mixture of antibodies) directed to one or more peptides of the invention. However, to date no-one has succeeded in isolating HCV virions from a human sample. In the future, should it prove possible to identify HCV virions in human samples and/or detect such virions immunologically, peptides of the invention and particularly antibodies directed thereto will be useful in such detection.

For detection of antibodies to HCV, a biological or other sample may be tested by being contacted with one or more peptides of the invention under appropriate conditions for specific binding, before binding is determined, for instance using a reporter system as discussed. Where a panel of peptides is used, different reporting labels may be employed for each peptide so that binding of each can be determined.

A specific binding member such as a peptide may be used to isolate and/or purify its binding partner antibody from a test sample, to allow for sequence and/or biochemical analysis of the antibody. Amino acid sequencing is routine in the art using automated sequencing machines.

39

A typical immunoassay may involve incubating a test sample with peptides according to the invention under conditions to allow formation of immune complexes if an appropriate antibody is present in the sample, and detecting the presence or

5   absence of immune complex.

As noted, although not technically feasible at the moment, in principle antibodies according to the present invention may be used to determine the presence or absence of HCV strains in

10   test samples, by assessment of binding of the antibodies to E2HVR1 epitopes if present in the sample.

A typical immunoassay may involve incubating a test sample with peptides or anti-idiotypic antibodies according to the

15   invention under conditions to allow formation of immune complexes if an appropriate antibody is present in the sample, and detecting the presence or absence of immune complex.

A sample may be tested for the presence of an antibody

20   directed to one or more peptides of the invention, using one or more such peptides (or polypeptide including such peptide) or one or more anti-idiotypic antibodies.

A biological or other sample may be tested by being contacted

25   with a peptide or polypeptide or anti-idiotypic antibody under appropriate conditions for specific binding, before binding is

40

determined, for instance using a reporter system as discussed.

The detection of formation of a binding complex in an
immunoassay in accordance with the present invention may be
5   performed using any available technique without limitation to
the scope of the invention. Some suitable techniques are
described above with reference to antibody labelling. Assays
may involve immobilising antibody or peptide, as the case may
be, on a suitable solid phase or support, such as latex
10   particles, magnetic or non-magnetic beads, a membrane, chip,
plastic, metal, silicon or glass surface, or any other
suitable material at the disposal of the skilled person.
Detection may be qualitative or quantitative. One or more
appropriate controls may be included, in accordance with
15   standard practice.

As noted already, peptides, polypeptides, antibodies and
nucleic acid in accordance with the present invention may be
formulated into compositions, and are useful in pharmaceutical
20   contexts. These compositions may include, in addition to one
of the above substances, a pharmaceutically acceptable
excipient, carrier, buffer, stabiliser or other materials well
known to those skilled in the art. Such materials should be
non-toxic and should not interfere with the efficacy of the
25   active ingredient. The precise nature of the carrier or other
material may depend on the route of administration, e.g. oral,

41

intravenous, cutaneous or subcutaneous, nasal, intramuscular, intraperitoneal routes.

Compositions for oral administration may be in tablet, capsule, powder or liquid form. A tablet may include a solid carrier such as gelatin or an adjuvant. Liquid pharmaceutical compositions generally include a liquid carrier such as water, petroleum, animal or vegetable oils, mineral oil or synthetic oil. Physiological saline solution, dextrose or other saccharide solution or glycols such as ethylene glycol, propylene glycol or polyethylene glycol may be included.

For intravenous, cutaneous or subcutaneous injection, the active ingredient will be in the form of a parenterally acceptable aqueous solution which is pyrogen-free and has suitable pH, isotonicity and stability. Those of relevant skill in the art are well able to prepare suitable solutions using, for example, isotonic vehicles such as Sodium Chloride Injection, Ringer's Injection, Lactated Ringer's Injection. Preservatives, stabilisers, buffers, antioxidants and/or other additives may be included, as required.

Branched peptides, such as MAP (Tam, J.P, 1988) may be used for the preparation of immunogens, either alone or linked to an appropriate carrier.

42

A linear peptide for use in raising an immune response may

also be linked to an appropriate carrier. Various methods of

coupling peptides to other molecules are known in the art,

including disulphide forming reagents (where the peptide

5 includes a cysteine - or a cysteine is added to the peptide

for this purpose), thio-ether forming coupling agents and so

on. Carriers include human serum albumin (HSA), tetanus

toxoid, other rather large proteins that have reasonable half-

lives under physiological conditions, and stable non-

10 proteinaceous molecules such as polysaccharides and copolymers

of amino acids.

An adjuvant may be included, such as alum, oil-in-water

emulsions or Freund's Adjuvant (Complete or Incomplete).

15 Cytokines may be used to potentiate immunogenicity of the

peptide or polypeptide composition.

Mimotope sequences may be cloned into the context of the HCV

envelope (E2) protein in order to use the natural folding

20 environment for correct presentation of the epitope or

epitopes to the immune system.

Naked DNA may be used for immunization (see e.g. Cohen, J,

1993), and one or more mimotope sequences may be cloned into

25 suitable vectors (see e.g. Major *et al.*, 1995). Naked DNA may

be delivered using direct injection or by use of gene-guns

43

(Yang *et al.*, 1990) or any other suitable technique.

Whether it is a polypeptide, antibody, peptide, nucleic acid molecule, small molecule or other pharmaceutically useful compound according to the present invention that is to be given to an individual, administration may be in an immunogenic amount, that is sufficient to raise an immune (particularly antibody) response in the individual, or in a "prophylactically effective amount" or a "therapeutically effective amount" (as the case may be, although prophylaxis may be considered therapy). A prophylactic effect is sufficient to potentiate the immune response of an individual to a subsequent challenge with HCV, E2HV polypeptide, or HVR1 peptide, or to a subsequent infection with HCV, preferably in the latter case (HCV infection) to sufficient to antagonise the infection, wholly or partially. Most preferably the effect is sufficient to prevent the individual from suffering one or more clinical symptoms as a result of subsequent HCV infection, and/or protect the individual from hepatitis C. A therapeutic effect is sufficient to potentiate the immune response of an individual to pre-existing HCV infection, preferably sufficient to antagonise the infection, wholly or partially. Most preferably the effect is sufficient to ameliorate one or more clinical symptoms, and/or cure the hepatitis C and/or reduce viral titre in the individual. The actual amount administered, and rate and time-course of

44

administration, will depend on the nature and severity of what is being treated. Prescription of treatment, e.g. decisions on dosage etc, is within the responsibility of general practitioners and other medical doctors, and typically takes account of the disorder to be treated, the condition of the individual patient, the site of delivery, the method of administration and other factors known to practitioners. Examples of the techniques and protocols mentioned above can be found in Remington's Pharmaceutical Sciences, 16th edition, Osol, A. (ed), 1980.

Further aspects of the invention provide methods of treatment including administration of a peptide, mixture of peptides, antibody molecule or mixture of antibody molecules, as provided, pharmaceutical compositions including such a peptide, mixture of peptides, antibody molecule or mixture of antibody molecules, and use of such a peptide, mixture of peptides, antibody molecule or mixture of antibody molecules, in the manufacture of a medicament for administration, for example in a method of making a medicament or pharmaceutical composition including formulating the specific binding member with a pharmaceutically acceptable excipient.

A composition may be administered alone or in combination with other treatments, either simultaneously or sequentially dependent upon the condition to be treated and the

45

availability of alternative or additional treatments.

One aspect of the present invention provides use of a peptide as disclosed in the manufacture of a medicament for raising in a mammal antibodies able to bind HCV HVR1 epitopes.

Another aspect provides a method of immunising a mammal against HCV infection, the method including administering a peptide or mixture of peptides to the mammal.

A still further aspect provides a method of (passively) immunising a mammal against HCV infection, the method including administering an antibody according to the invention to the mammal, or a mixture of antibodies.

Similarly, further aspects of the invention provide a method of treating a mammal with an HCV infection, the method including administering a peptide according to the invention, or a mixture of peptides, or an antibody, or a mixture of antibodies, to the mammal.

The antibodies may be anti-idiotypic antibodies.

Aspects and embodiments of the present invention will now be illustrated further and experimentally exemplified with reference to various figures. Further aspects and embodiments

46

of the present invention will be apparent to those of ordinary skill in the art.

In the figures:

Figure 1(A) illustrates derivation of the consensus pattern of the 234 natural variants of the HCV HVR1 sequences used in this work. Non shaded residues within the box account alone for about 80% of the observed variability. Residues are listed in decreasing order of observed frequency from top to bottom.

Figure 1(B) shows the composition in the initial HVR1 peptide library which was displayed on bacteriophage (SEQ ID NO: 1).

Figure 2 shows reactivity of phage pools yielded by the first round of affinity selection to antibodies present in the selecting sera. For each serum sample ($\sigma 1$, $\sigma 4R$, $\sigma 3$, $\sigma 2P$, $\sigma 2R$, $\sigma 3R$ and σN) antibody recognition of the phage pools (pool 1, 4R 3, 2P, 2R, 3R and N), wild type phage (wt) and the unselected library (HVR1 lib) was measured. Average values (A_{405nm}) from two independent experiments have been determined.

Figure 3 shows distribution of HCV-specific phage selected from the HVR1 library as function of their frequency of

reactivity with sera from infected patients. Binding is shown

for phage enriched by one (top panel) or two (bottom panel)

cycles of affinity selection to antibodies present in twenty

human sera different from those used for the selections. For

5   each serum, average values (A_{405nm}) from two independent

experiments have been determined on the selected phage and on

wild type phage. Values were considered statistically

significant when differing more than $3\sigma_{max}$ (p<0.003) from the

background signal observed for the wild type phage. Each

10 histogram represents the number of phage (shown on the

vertical axis) reacting with the indicated number of sera

expressed as percentage over total number of tested samples

(horizontal axis).

15 Figure 4 shows that the selected mimotopes are frequently

recognized by antibodies present in human sera from HCV

infected patients. Binding of the selected mimotopes to

antibodies present in human sera was detected by ELISA on

immobilised phage. Mimotopes' names are indicated at the top

20 of each column. For each serum (indicated on the left of each

row), average values (A_{405nm}) from two independent experiments

have been determined. Results are expressed as the difference

between the average value of the tested phagotope and that of

wild type phage. Positive values are indicated in bold.

25 Values were considered statistically significant when

48

differing more than $3\sigma_{max}$ (p<0.003) from the background signal

observed for the wild type phage. The frequency of reactivity

of each mimotope and that resulting from the sum of the

reactivities observed with all four mimotopes are shown at the

5   bottom of each panel.

Figure 4(A) shows reactivity of selected mimotopes with the

panel of twenty HCV patients' sera used for the screening

step.

10

Figure 4(B) shows reactivity of selected mimotopes with an

additional panel of sera from HCV-infected viremic patients.

Figure 4(C) shows reactivity with sera from non viremic

15   patients that were scored positive for anti-HCV antibodies

using commercially available kits.

Figure 5 shows correlation between the S-score and the

frequency of reactivity of the selected mimotopes. The

20   straight line represents the linear least square fit of the

data. The correlation coefficient is 0.79.

Figure 6 shows that the selected mimotopes are antigenic

mimics of a large number of naturally occurring HVR1.

25   Antibodies from a pool of sera from HCV infected patients were

immunopurified on MAPs reproducing the sequence of selected

mimotopes (indicated at the top of the figure). Reactivity of

equal amounts of the immunopurified antibodies was measured by

ELISA on a representative panel of HVR1 sequences synthesized

5   as MAPs (indicated in the left column). Average values from

two independent experiments were determined. Values were

considered statistically significant when two criteria were

contemporarily fulfilled: (1) values were differing more than

$3\sigma_{max}$ (p<0.003) from the background signal observed on two

10   unrelated peptides; (2) values were differing more than $3\sigma_{max}$

(p<0.003) from the average signal observed using ten sera from

non infected individuals on each peptide representing a

natural HVR1. Grey boxes indicate signals differing from

those observed on the unrelated MAPs between 0.15 and 0.5 OD

15   (405nm); black boxes indicate values differing more than 0.5

OD (405nm). The level of cross-reactivity of each pool of

immunopurified antibodies is indicated at the bottom of each

column.

20   Figure 7 shows correlation between mimotope sequence and

cross-reactivity.

Figure 7(A) shows the sequences of the mimotopes used in the

analysis (SEQ ID NOS: 149, 27, 3, 10, 20, 6, 23, 29 and 19).

25

Figure 7(B) shows correlation between the S-score of the

mimotopes and the cross-reactivity of immunopurified human

antibodies with a panel of 43 natural HVR1 sequences. The

straight line represents the linear least square fit of the

5   data. The correlation coefficient is 0.86.

Figure 8 shows that the selected mimotopes are immunogenic

mimics of a large number of naturally occurring HVR1.

Reactivity of sera from mice immunised with single HVR1

10   mimotopes (Figure 8(A)) and mixtures of mimotopes (Figure

8(B)) in the form of MAP was assayed by ELISA on the panel of

natural HVR1 sequences (indicated in the left column).

Immunizing mimotopes are shown in the first row. MIX1

includes mimotopes R9, F78, H1 and D6; MIX2 contains M122 and

15   G31 peptides; MIX3 is composed of all six MAPs. Titres

(defined as the dilution required to obtain half maximal

signal in ELISA on the homologous peptide) are shown in the

second row. Sera were diluted 1:100. Average values from two

independent experiments have been determined. Values were

20   considered statistically significant when differing more than

$3\sigma_{max}$ (p<0.003) from the background signal observed on two

unrelated peptides. Grey boxes indicate signals differing

from those observed on the unrelated MAPs between 0.15 and 0.5

OD (405nm); black boxes indicate values differing more than

25   0.5 OD (405nm). The level of cross-reactivity of each serum

is indicated at the bottom of each column.

Figure 9 illustrates plasmids employed in *in vivo* nucleic acid immunisation experiments described in Example 6 (SEQ ID NOS: 5   29, 37, 3, 36, 19, 6, 20, 38, 23, 27 and 10).

EXAMPLE 1 - Design and construction of a specialised phage library mimicking the HVR1 variability

10   A multiple sequence alignment of 234 unique HVR1 sequences extracted from the sequence databases was made to characterise the variation in residue composition at each of the N-terminal 27 positions of the HCV E2 glycoprotein. A sequence pattern emerged from this analysis (Figure 1A) allowing the definition 15   of a degenerate consensus sequence. A synthetic repertoire of HVR1 sequences was designed to contain such conserved constraints while reproducing the observed natural variability in the remaining positions.

20   A "consensus-profile" accounting for approximately 80% of the total sequence variability was derived by selecting the most frequent residues at each position. When similar amino acids were present at a given position, only one was chosen as representative of the variability, preferring those residues 25   which could more effectively form interactions. For example, in position 5 both Ser and Thr are present in the natural

repertoire, but only Thr was selected to design the library (Figure 1). In some cases, a residue not present in the consensus was included in the library to better mirror the overall variability. For example, Thr was included in position 3 to account for the presence of Ser, Thr, Asn in the natural repertoire of HVR1s.

The resulting final consensus profile (Figure 1B) has a complexity of 9×10^7 very close to the upper practical limit (about 10^8) of current DNA cloning and transformation techniques. The amino acid most frequently observed in the natural repertoire was always included with the exception of position 1, (where Gln and Thr were selected although Glu is the most frequently observed amino acid). Eight positions (2, 6, 7, 16, 19, 20, 23 and 26) where kept constant given the high local sequence conservation throughout the 234 natural HVR1 variants. Noteworthy also is the total absence of negatively charged residues. With the exception of position 1, where Gln was chosen to represent the His, Glu, Asp, Gln, Asn group, no acidic residues were present within the 80% fraction. Qualitatively, the profile can be described as a generally more variable central region flanked by N-terminal and C-terminal tails containing conserved elements.

Construction of the library proceeded by cloning a degenerated synthetic oligonucleotide as a fusion to the 5' end of the

53

gene coding for the major coat protein (pVIII) in a phagemid

vector for M13 display (see Materials and Methods). About 2 x

10^8 independent transformants were obtained. To verify the

quality and complexity of the library (HVR1 library), the

inserts of fifty-six randomly chosen individual clones were

sequenced. This analysis led to the following results:

(1) all clones displayed different sequences;

(2) 63% of the clones contained full-length inserts while the

remaining ones had small deletions;

(3) none of the sequenced clones encoded for peptides

corresponding to known HVR1 from viral isolates, searched on

15 March 1998.

From these data it was inferred that the library has a

complexity close to the number of individual transformants.

EXAMPLE 2 - Identification of HVR1 mimotopes frequently

reacting with HCV patients' sera

The more complex and diverse the repertoire of antibodies used

for the selection, the higher should be the probability to

enrich phage recognised by many different antibodies against

HVR1 epitopes. Sera from chronically infected, viremic

patients appear to meet these requirements as these

individuals have a rather long history of viral persistence,

54

during which a large number of HCV variants have been generated and have challenged the immune system, presumably leading to the accumulation of a highly heterogeneous population of anti-HVR1 antibodies.

Eight sera from chronic patients infected by viruses of five different genotypes: 1a, 1b, 2a, 2b, 3a (Simmonds et al., 1993) were used to perform six affinity selections of the HVR1 library (Table 1). As control, a serum from a non infected individual was also used. Pools of phage obtained from all seven selections were amplified and tested for their reactivity to each of the selecting sera in ELISA. The results of this experiment showed a significant enrichment of phage recognised by the selector antibodies, as evidenced by the increase in reactivity with respect to the unselected library (Figure 2). In most cases, phage pools enriched by HCV sera reacted with more than one patient's serum. Peptides recognised by antibodies unrelated to HCV infection were also enriched from the library. In fact, the pool of phage selected with the control serum has a higher reactivity with this serum than the unselected library (Figure 2). However, patients' sera drove selection toward HCV-related mimotopes as no reactivity to phage pools enriched by HCV sera was detected using sera from healthy individuals (Figure 2 and data not shown).

To gain insight into the frequency of reactivity of the selected mimotopes with different patients' sera, forty individual clones from two pools (4R and 2R, Table 1) were randomly chosen and tested for their reactivity in ELISA with a panel of twenty sera from HCV infected patients different from those used for the selection. An equivalent number of sera from non-infected healthy controls were used to assess the specificity for anti-HCV antibodies. Twenty-four clones turned out to be HCV-specific. Their distribution as a function of their frequency of reactivity with patients' sera is reported in Figure 3 (upper panel). Among them, phage reacting with more than one serum were identified; some of these were recognised by up to 55% of the tested sera.

To further improve the isolation of mimotopes reacting with many different anti-HVR1 antibodies, the enriched phage pools were subjected to a second round of affinity selection using patients' sera different from those used for the first round. In this way nine new pools were generated (Table 1) and analysed by ELISA. As before, a general increase in reactivity with the selector antibodies was observed. In addition, all second round phage pools reacted more frequently than those selected in the first round with a panel of sera from HCV-infected patients different from those used for either selection, reflecting a higher recognition frequency of the isolated peptides. This was confirmed by comparing the

56

reactivity with HCV sera of clones randomly chosen among those eluted after one round of affinity selection (Figure 3, upper panel) and those obtained by re-selecting them with a second different serum (Figure 3, lower panel). Not only the frequency, but also the distribution of reactivity appeared to be significantly different after the second selection step. While recognition of phage from the first selection appears to be rather scattered, clones isolated through two rounds of selection show a bell-shaped distribution of their frequency of reactivity with an average value of 60% (Figure 3, lower panel), indicating that the whole phage population had indeed acquired more of the desired binding properties. It was decided to omit additional selection cycles to avoid introduction of a bias toward biologically favoured phage during amplification.

A total of one hundred and seventy one clones reacting exclusively with HCV sera were identified by screening all second-round pools. Their distribution as a function of the recognition frequency by HCV sera mirrored that of the subset displayed in Figure 3, lower panel, with the best clones reacting with 80% of the tested samples. More importantly, the profiles of reactivity of the selected mimotopes highlight another relevant feature. Despite their quantitative similar overall frequency of recognition by the HCV sera, different clones display a characteristic pattern of reactivity with the

57

net result that few mimotopes can score for the presence of
anti-HVR1 antibodies in all tested sera (Figure 4A).

Next, it was verified whether the observed high frequency of
recognition by HCV sera was limited to the tested patients'
population or whether it reflected an intrinsic property of
the selected mimotopes. For this purpose another set of sera
from infected patients was assayed by ELISA revealing that
both the frequency of reactivity of each individual phage and
the total coverage of the sera remained unaltered (Figure 4B).

HCV infected individuals who have resolved the infection most
likely came in contact with a lower number of viral variants
and presumably developed a narrower spectrum of variant-
specific anti-HVR1 antibodies than chronically infected
patients. This is supported by the finding that sera from the
former population react with synthetic peptides reproducing
the HVR1 of natural isolates much more rarely than those of
chronically infected viremic patients (Scarselli et al.,
1995). Therefore, non viremic sera could constitute a better
and more stringent test for assaying the cross-reactivity of
HVR1 mimotopes with different anti-HVR1 antibodies. Some of
the selected mimotopes were thus tested against forty-one
samples from HCV seropositive individuals who were repeatedly
found negative for the presence of viral RNA in the blood.
Again, the mimotopes reacted with many of these sera albeit at

a lower frequency than that observed with sera from viremic

patients (compare Figures 4(A), 4(B) and 4(C)). These data

provide an indication of the ability of the selected mimotopes

to cross-react with a large number of different anti-HVR1

5   antibodies.

EXAMPLE 3 - Determination of a relationship between the

sequence of the selected HVR1 mimotopes and their frequency of

reactivity with HCV sera.

10

The inventors wished to verify whether the amino acid sequence

of the selected clones correlates with their frequency of

reactivity. No obvious pattern arises from a visual

comparison of the sequences so it was decided to analyse

15   separately the sequence patterns of the least and most

frequently reacting clones.

Defined as "weak" were the 24 clones that only reacted with

less than 3 sera and defined as "strong" were the 27 reacting

20   with more than 11 sera. The amino acid frequencies at each

position of weak and strong clones are listed in the Materials

and Methods section below, and in Table II.

There is a clear trend for some positions to be occupied by

25   different amino acids in the sets of weak and strong clones

and this allowed us to heuristically define a position-based

59

scoring system described in Materials and Methods (see below).
The higher is the score of a clone (S-score) the more similar
its sequence is to those of the strong clones and the more
different from those of the weak ones. As shown in Figure 5,
the S-score correlates reasonably well (correlation
coefficient = 0.75) with the experimentally determined
frequency of reactivity of each clone. It should be
emphasised that the S-score was calculated using only the
sequences of the "weak" and "strong" clones (51 out of 171),
but it correlates well with the frequency of reactivity of all
clones. Interestingly, a nearly identical result (correlation
coefficient = 0.72) can be obtained using only 6 positions
where the residue preference of the weak and strong mimotopes
differ most (positions 3, 11, 18, 21, 22, 24).

*EXAMPLE 4 - The HVR1 mimotopes antigenically mimic a large
number of HVR1 variants from HCV isolates.*

The inventors set to measure the cross-reactivity of human
antibodies which recognise the mimotopes, with sequences
representing naturally occurring HVR1.

For this purpose the mimotopes were used as immunoadsorbents
to purify the specific antibodies from the bulk of anti-HVR1
present in infected patients' sera. Mimotopes R9, F78, M122,
R6, B14, G31, H1 and D6 (Figure 7) were chosen for these

60

experiments because they were among those which displayed the highest frequency of reactivity with the HCV sera. Mimotope N5 which was recognised by a significantly lower percentage of HCV sera than the average "good" mimotopes (35% and 60-80%,

5   respectively) was also used.

Although some lymphocyte cell lines have been shown to support limited replication of HCV (Shimizu et al., 1992), these systems are not suited for viral propagation and for a

10 detailed study of the cross-reactivity of anti-HVR1 antibodies. Therefore, the cross-reactivity of the immunopurified antibodies on a panel of synthetic peptides reproducing natural HVR1 variants which approximately cover the observed sequence variability was determined.

15

To this end, a multi-dimensional cluster analysis (Casari et al., 1995) was performed on the same set of 234 aligned natural HVR1 sequences used for the construction of the library. Out of these, forty-three sequences nearly

20 homogeneously distributed over the HVR1 "sequence space" were chosen (see Materials and Methods below) and synthesised as multiple antigenic peptides (MAP; Tam, J.P, 1988; Pessi et al., 1990). A pool of eight sera from infected patients collectively reacting with the entire panel of forty-three

25 MAPs was used as a source of antibodies. The immunopurified antibodies displayed the same reactivity to the mimotope used

61

for the purification compared to the total serum.   In

contrast, no reactivity to a recombinant HCV core antigen or

to the antigens included in a commercially available kit (see

below in Materials and Methods) was retained after

5   purification thus testifying to the efficiency and the

specificity of the purification.

All immunopurified antibodies reacted with a significant

number of natural HVR1 sequences with mimotope R9 yielding

10   antibodies cross-reacting with 79% of natural HVR1 (Figure 6).

As most immunopurified antibodies also displayed some non-

overlapping reactivities to the natural sequences, an even

higher level of overall cross-reactivity (88%) can be reached

by adding up the individual contributions of antibodies

15   purified from only three different mimotopes (R9, F78 and

M122, Figure 6).   From these data it was concluded that a

limited set of HVR1 mimotopes can antigenically mimic a large

number of natural HCV HVR1 variants.

20   Antibodies immunopurified by mimotopes with higher S-score,

and consequently with a higher frequency of reactivity, also

showed to be more cross-reactive.   Eight mimotopes were used

and, as shown in Figure 7B, the correlation between this

sequence related score and the cross-reactivity of the

25   corresponding antibodies is very good (r = 0.86; Figure 7B).

EXAMPLE 5 - The HVR1 mimotopes induce antibodies recognising many natural HVR1 variants.

A problem prior to the present work was the generation of
immunogens able to induce antibodies cross-reacting with the
largest number of HCV HVR1 natural variants. The immunogenic
potential of some of the best HVR1 mimotopes (R9, F78, M122,
G31, H1 and D6) was investigated by injecting them in mice
both as whole purified phage and, outside of the original
context in which they were selected, as MAPs.

MAPs turned out to be much more potent immunogens presumably
due to the insufficient loading of HVR1 peptides on each phage
as indicated by mass spectrometry analysis (less than 1% of
the total pVIII content). Some variability in the efficiency
of immunization was observed between the mimotopes as shown by
the difference in titre, with F78 being able to induce
antibody titres higher than 1/100,000 as measured by ELISA on
the same peptide used for the immunisation (Figure 8A). Anti-
HVR1 mimotope sera were then tested for their ability to
recognise heterologous HVR1 variants by ELISA on the panel of
forty-three MAPs reproducing HCV sequences from natural
isolates. Most of these MAPs were recognised by the immune
sera (Figure 8A), while no reactivity,was observed on
unrelated control peptides.

The cross-reactivities of the sera of mice immunised with

mimotopes did not rank as that of human antibodies

immunopurified with the same mimotopes. However, mimotope N5,

which showed significantly lower levels of reactivity in both

5   types of assays, revealed to be a much less efficient

immunogen, leading to an anti-HVR1 response able to recognize

only a minority of the natural HVR1 sequences (Figure 8A).

The extent of cross-reactivity of the immune sera generally

10   reflects the immunogenicity of the individual MAPs as, in most

cases, a higher titer corresponds to a higher level of cross-

reactivity (Figure 8A). Nevertheless, titer alone cannot

always explain the difference in cross-reactivity and in the

pattern of reactivity displayed by the mimotope induced sera

15   as clearly shown in the case of the anti-G31 serum which has a

lower titer than the anti-F78, but reacts with a larger number

of natural HVR1 peptides. Similarly, the anti-D6 serum

displays the same level of cross-reactivity of the anti-R9

despite a three fold lower titer (Figure 8A).

20

The pattern of reactivity displayed by each antiserum is only

partially overlapping with that of the others, and, in some

cases, unique reactivities were observed. As a consequence of

this feature of the induced sera, by adding up all the

25   reactivities, almost all natural HVR1 peptides are recognized

(91%, Figure 8A). This observation is a significant

64

improvement toward the goal of generating broadly reacting antibodies, provided one can obtain a similar increase in cross-reactivity a single immunization with a cocktail of mimotopes. Therefore, three groups of Balb/c mice were

5 immunised with mixtures of mimotopes. Mixture 1 contained mimotopes R9, F78, H1 and D6; mixture 2 was composed of mimotopes M122, and G31, while mixture 3 comprised all six mimotopes. All three mixtures were immunogenic, and induced highly cross-reactive antisera (Figure 8B). Each of the three

10 antisera displayed the same or an even higher cross-reactivity than that measured by adding up the reactivities of the antisera induced by each of the mimotopes included in the mixture (84% vs 84% for MIX1, 84% vs 81% for MIX2 and 95% vs 91% for MIX3, Figure 8B). The titers of these sera although

15 high, were not better than those obtained with individual MAPs. It was therefore concluded that the ability of inducing highly cross-reacting response is not simply a consequence of the efficiency of the immunisation.

20 *MATERIALS AND METHODS*

Human sera

Human sera from HCV-infected patients and from healthy

25 individuals were characterised for the presence of antibodies to HCV by a second-generation HCV ELISA test system (Ortho-HCV

65

ELISA, Ortho Diagnostic Systems, Bersee, Belgium) and by a

first generation dot blot immunoassay (RIBA-HCV test, Chiron

Co., Emeryville, CA). The presence of HCV RNA was detected by

nested reverse transcription-PCR using conserved primers

5   localised in the 5' non-coding region of the viral genome and

total RNA extracted from 100µl of serum as previously

described (Silini et al., 1995).

Construction of the HVR1 library

10

To back-translate the consensus profile described above with

reference to Figure 1B into the corresponding nucleotide

sequence, the *E. coli* codon usage table was employed selecting

codons most frequent in highly expressed genes. To facilitate

15   insertion of the library into the phagemid vector two

additional constant sequences containing the recognition sites

for the restriction enzymes PacI and NotI were added 5' and 3'

to the 81bp segment, respectively giving a total of 116 bp.

Absence of NotI and PacI restriction sites in the

20   backtranslation of the consensus profile was verified by

computer-assisted sequence analysis. For the chemical

synthesis a codon-based "split-and-pool" method (Cormack et

al., 1993) was applied in order to keep both library

composition and complexity at the desired level. The 116 bp

25   oligonucleotides were amplified with primers complementary to

the flanking constant sequences in a 9600 DNA Thermal Cycler

(Perkin-Elmer Cetus, Foster City CA). The PCR product was digested with PacI and NotI enzymes and gel-purified. The recovered DNA fragment was cloned between the PacI and NotI sites of the pel8PN phagemid vector (a derivative of pc89;

5   Felici et al., 1991) downstream of the pelB secretion leader and upstream of the entire gene VIII coding sequence. Recombinant phagemids were electroporated into DH10B competent cells. Since DH10B cells cannot be infected by filamentous phage and do not allow for blue/white selection, transformed

10 cells were collected and plasmid DNA was prepared. This DNA was used to transform by electroporation XL1-blue competent cells. Ampicillin resistant colonies were scraped from the plates and resuspended in LB/100 µg ampicillin/ml and 10% (v/v) glycerol. A portion of this bacterial suspension was

15 inoculated into six litres of LB medium containing 100 µg ampicillin/ml at 0.05 O.D.$_{600nm}$ and grown with vigorous shaking until 0.25 O.D.$_{600nm}$ was reached. The culture was then superinfected with M13K07 helper phage and grown for additional five hours to obtain the phage particles in the

20 supernatant. The phage were precipitated twice with polyethylene glycol and purified by equilibrium centrifugation in CsCl as described (Felici et al., 1991).

DNA-sequencing was performed as described (Bartoli et al.,

25 1996) using an Applied Biosystem 373 DNA sequencer.

Library affinity selection

ELISA multiwell plates (Nunc Maxisorp, Roskilde, Denmark) were coated overnight at 4°C with 0.5 µg/ml of anti-human (Fc-

5   specific) polyclonal Ab (Immunopure goat anti-human IgG Fc-specific; Pierce, Rockford, IL) in 50 mM NaHCO3 pH 9.6. The plates were washed with PBS/0.1% Tween 20 (washing buffer) and incubated for 1 hr at 37°C with 100 µl/well of blocking buffer (5% non fat dry milk, PBS/0.05% Tween 20). 1 µl of human

10   serum diluted 1:100 in PBS /0.1% BSA was added to each well and incubated overnight at 4°C. After washing, 10^{12} particles of U.V. killed M13K07 diluted in PBS/0.1% Tween 20, 0.01% BSA, were then added to each well and incubated for 4 h at 4°C. After this pre-incubation, 10^{12} particles/well of HVR1 library

15   were added and incubated overnight at 4°C. Unbound phage were removed and several rounds of washing were performed. Bound phage were eluted with 200 µl of elution buffer (0.1M HCl adjusted to pH 2.5 with glycine, 1 mg/ml BSA) and neutralised with 2M Tris-HCl pH 9. Eluted phage were titrated by

20   infection of XL1-blue bacteria and the percentage of clones containing a productive insert was determined by plating infected bacteria on X-gal/IPTG indicator plates (Felici et al., 1991). After amplification (see above) enriched phage were subjected to a second cycle of affinity selection

25   following the same procedure.

Sequence analysis of the mimotopes and definition of the S-score

5   Out of a total of 193 selected clones, 171 showed no point

mutation (with respect to the original library design) or

deletions and were divided in three classes: 24 weak clones

(reacting with less than 3 out of the 20 tested sera), 27

strong clones (reacting with at least 12 sera) and

10   intermediate (the remaining clones).

For each amino acid at position i of a 27-mer amino acid

sequence, we call Fs(i, aa) and Fw(i, aa) the observed

frequency of the same amino acid in position i of the set of

15   strong and weak clones, respectively.

The frequency values are shown in Table II.

S-score(i) was then defined as the difference between the

20   square roots of Fs(i,aa) and Fw(i,aa). The sum over the all

27-mer sequence of S-score(i) is our sequence based S-score.

In practice:

$$S\text{-score} = \sum_i (\sqrt{Fs(i,aa)} - \sqrt{Fw(i,aa)})$$

where aa is the observed amino acid in position i of the

25   sequence for which the S-score is calculated. The square root

of the frequencies was used to amplify differences. For

clones where a point mutation or deletion had occurred, the

corresponding position was omitted in the score calculation.

5   *Selection of a representative set of natural HVR1 sequences*

The NS1 HVR1 sequence from the HCV BK strain (residues 384-

411) was used to search various databases (on 13 December

1995), both protein (SwissProt, PIR and Genpept, the latter

10   representing assigned open reading frames from Genbank and

EMBL) and nucleotide sequence (EMBL, Genbank and EST).

Duplicated and incomplete sequences were removed from the list

of matching sequences to obtain a unique set of 234 natural

HVR1 sequences.

15

Principle component analysis was used to select 40 sequences

homogeneously distributed over the set. First, all pairwise

distances between the 234 sequences were calculated using the

first six eigenvalues calculated using Sequencespace (Casari

20   et al., 1995). Sequences with the smallest distances to

neighbouring sequences were eliminated in a stepwise procedure

until only 40 sequences remained. Projections into two

dimensions along all possible pairs of Eigenvectors showed

that the set of 40 sequences did not cluster and were

25   homogenously distributed.

70

Accession numbers and sequences are:

```
 1 Genbank:D12967  QTRTVGGQMGHGVRGLTSLFSAGSARN  bp  46- bp 126  (SEQ ID NO: 150)

 2 PIR:PC1193       STHVTGALQGRAAYGITSFLSHGPSQK  aa  16- aa  42  (SEQ ID NO: 151)

 3 Genbank:D00574  HTRVTGGVQGHVTSTLTSLFRPGASQK  bp1240- bp1320  (SEQ ID NO: 152)

 4 Genbank:L19383  ETHTSGGSVARAAFGLTSIFSPGAKQN  bp  46- bp 126  (SEQ ID NO: 153)

 5 Genbank:M62381  ETHVTGGSAGRTTAGLVGLLTPGAKQN  bp1426- bp1506  (SEQ ID NO: 154)

 6 Genbank:U24616  ATYTTGGSAAKTAHRLASFFTVGPKQD  bp  22- bp 102  (SEQ ID NO: 155)

 7 PIR:C48776       DTHVVGGATERTAYSLTGLFTAGPKQN  aa  13- aa  39  (SEQ ID NO: 156)

 8 Genbank:U24607  GTTCQGGVYARGAGGIASLFSVGANQK  bp  22- bp 102  (SEQ ID NO: 157)

 9 PIR:D48766       RTLSFGGLPGHTTHGFASLSAPGAKQN  aa  13- aa  39  (SEQ ID NO: 158)

10 Genbank:X60573  RTILMAGRQAEVTQSFPGLFSLAPSQK  bp  46- bp 126  (SEQ ID NO: 159)

11 Genbank:D43650  NTHAMGGVVARSAYRITSFLSPGAAQN  bp   1- bp  81  (SEQ ID NO: 160)

12 PIR:PQ0835       STRITGGSMARDVYRFTGFFARGPSQN  aa   6- aa  32  (SEQ ID NO: 161)

13*Genbank:S73387  GTHTIGGSQAQQANRFVSMFSRGPSQK  aa 190- aa 216  (SEQ ID NO: 162)

14 Genbank:D10934  NTYVTGGAAARGASGITSLFSRGPSQK  bp1491- bp1571  (SEQ ID NO: 163)

15 Genbank:D31972  NTYASGGAVGHQTASFVRLLAPGPQQN  bp1409- bp1489  (SEQ ID NO: 164)

16 Genbank:U14231  ETHTTGGEAARTTLGIASLFTSGANQK  bp 103- bp 183  (SEQ ID NO: 165)

17 Genbank:U24602  ETHTTGGSAARATFGIANFFTPGAKQN  bp  22- bp 102  (SEQ ID NO: 166)

18 Genbank:L19380  ETYTSGGSAAHTTSGFVSFFSPGAKQN  bp  46- bp 126  (SEQ ID NO: 167)

19 Genbank:M74888  GTTRVGGAAARTTSSFASLLTHGPSQN  bp1147- bp1227  (SEQ ID NO: 168)

20 Genbank:L12354  NTHTVGAAASRSTAGLTSLFSIGRSQK  bp1468- bp1548  (SEQ ID NO: 169)

21 Genbank:X79672  NTRVTGGVQSRTTGTFVGLFTPGPSQR  bp   1- bp  81  (SEQ ID NO: 170)

22 PIR:A48776       NTHVSGGRVGHTTRSLTSFFTPGPQQK  aa  13- aa  39  (SEQ ID NO: 171)

23 Genbank:D12952  STRVSGGQQGRAAHSLTSLFTLGASQN  bp  46- bp 126  (SEQ ID NO: 172)

24 Genbank:D16566  STRITAQAEGRGASTLTSLFTSGASQK  bp   8- bp  88  (SEQ ID NO: 173)

25 Genbank:M84754  STIVSGGTVARTTHSLASLFTQGASQK  bp1491- bp1571  (SEQ ID NO: 174)

26 Genbank:D14853  ETRVTGGAAGHTAFGFASFLAPGAKQK  bp1491- bp1571  (SEQ ID NO: 175)

27 Genbank:S24080  NTYVTGGSAGRAVAGFAGLLQPGAKQN  bp  46- bp 126  (SEQ ID NO: 176)

28 Genbank:S35631  ETHSVGGSAAHTTSRFTSLFSPGPQQN  bp 580- bp 660  (SEQ ID NO: 177)

29 Genbank:S62395  ETHVTGGSAASTTSTLTKLFMPGASQN  bp  43- bp 123  (SEQ ID NO: 178)

30 Genbank:S70291  QTRTVGGANARNTYGLTTLFTTGPKQN  bp   1- bp  81  (SEQ ID NO: 179)
```

71

```
31 Genbank:D88472   GTTTVGSAVSSTTYRFAGMFSQGAQQN  bp1485- bp1565  (SEQ ID NO: 180)

32 Genbank:D10687   NTHTVGGTEGFATQRLTSLFALGPSQK  bp1180- bp1260  (SEQ ID NO: 181)

33 Genbank:D43651   NTHVTGGVVARNAYRITTFLNPGPAQN  bp  39- bp 119  (SEQ ID NO: 182)

34 Genbank:D14305   HTYTTGGTASRHTQAFAGLFDIGPQQK  bp1427- bp1507  (SEQ ID NO: 183)

35 Genbank:X60590   KTHVTGMVAGKNAHTLSSIFTSGPSQN  bp  46- bp 126  (SEQ ID NO: 184)

36 Genbank:D30613   GTHVTGGKVAYTTQGFTSFFSRGPSQK  bp1491- bp1571  (SEQ ID NO: 185)

37 Genbank:X53131   ETYTSGGNAGHTMTGIVRFFAPGPKQN  bp 802- bp 882  (SEQ ID NO: 186)

38 Genbank:U24619   STYSMGGAAAHNARGLTSLFSSGASQR  bp  22- bp 102  (SEQ ID NO: 187)

39 Genbank:M62382   ETHVTGGSAGRSVLGIASFLTRGPKQN  bp1426- bp1506  (SEQ ID NO: 188)

40 Genbank:D88474   ETYIIGAATGRTTAGLTSLFSSGSQQN  bp1488- bp1568  (SEQ ID NO: 189)
```

*Sequence 13 corresponds to the translated amino acid sequence
(aa190-aa216) reported in the CDS feature of Genbank entry
S73387.

Three additional sequences were also synthesized as MAPS: Two
sequences are derived from the pedigreed HCV inoculum H77
(Figure 2 of Farci et al., 1994):

```
41 (H77-1)        ETHVTGGNAGRTTAGLVGLLTPGAKQN  bp   1- bp  81  (SEQ ID NO: 190)

42 (H79)          ETHVTGGSAGHTAAGIASFFAPGPKQN  bp   1- bp  81  (SEQ ID NO: 191)
```

and one from the major isolate of a patient whose
immunoreaction has been characterized (Scarselli et al.,
1995):

```
43 Genbank:X79669  NTRVTGGVQSHTTRGFVGMFSLGPSQR  bp   1- bp  81  (SEQ ID NO: 192)
```

Phage preparation and ELISA

5   Phage supernatants were prepared from XL-1 blue infected cells

as previously described (Folgori et al. 1994). ELISA were

performed according to Dente et al., (1994) using 25 µl of

phage supernatant/well. Sera were diluted 1:100 if not

otherwise specified and revealed by addition of species-

10 specific anti-IgG (Fc-specific) alkaline phosphatase-

conjugated secondary antibodies (Sigma A-9544; dilution 1:5000

in ELISA blocking buffer). Results were recorded as

differences between $O.D._{405\ nm}$ and $O.D._{620\ nm}$ by an automated ELISA

reader (Labsystems Multiskan Bichromatic, Helsinki, Finland).

15

ELISA with phage pools were performed in the same way by using

equivalent amounts (10^{10} ampicillin transducing units) of

amplified phage after CsCl purification (see above).

100µl of MAPs representing natural HVR1 sequences were used to

20 coat ELISA plates (Nunc Maxisorp, Roskilde, Denmark) at a

final concentration of 10µg/ml in coating buffer (50mM $NaHCO_3$

pH 9.6). After blocking of free binding sites, 100µl/well of

sera or affinity-purified antibodies were added. Mouse and

rabbit sera were tested at final 1:100 dilution in blocking

25 buffer; affinity purified antibodies were tested at final

concentration of 150 ng/ml. Plates were incubated overnight

at 4°C. After washing, 100 µl/well of alkaline phosphatase

conjugated secondary antibodies (goat anti-mouse IgG Sigma A-

7434 diluted 1:2000; goat anti rabbit IgG Sigma A-8025 diluted

1:5000; goat anti human IgG Sigma A-9544 diluted 1:5000) were

5   added and incubated one hour at room temperature. Plates were

washed and alkaline phosphatase revealed as described above.

Affinity purification of antibodies from human sera

10   Multiple antigenic peptides reproducing the sequence of

different mimotopes were used since they showed the same

binding profile with HCV sera in ELISA as the phage, but

proved to be more efficient in the affinity selection of the

antibodies. Activated CH Sepharose 4B column (Pharmacia

15   Biotech 17-0490-01) was coupled with the MAP of interest at

the ratio of 1g of dried Sepharose/1mg of MAP in coupling

buffer (0.1 M NaHCO$_3$ pH8/0.5M NaCl). Coupling was followed by

blocking of free amino-groups with 0.1M Tris-HCl pH8. Sample

was loaded as a pool of eight HCV sera diluted 1:5 in coupling

20   buffer. After adsorption at room temperature and extensive

washing with PBS, bound antibodies were eluted with 0.1M

glycine-HCl pH 2.7 supplemented with BSA at final

concentration of 10µg/ml and immediately neutralised by 2M

Tris-HCl pH9.4. The concentration of eluted antibodies was

25   determined by ELISA using as standard human IgG (Sigma I-

74

2511). Affinity-purified antibodies were checked for their reactivity in ELISA with the mimotope used for the purification (both in the form of MAP and phage) and, as control, with HCV-unrelated MAPs. The specificity of the purification was further confirmed by testing the eluted antibodies by ELISA on recombinant bacterially expressed HCV core protein (Prezzi et al., 1996) and by the second-generation HCV ELISA test (Ortho Diagnostic Systems, Bersee, Belgium). The total amounts of immunoglobulins recovered in each affinity purification from a standard amount of 1 ml of serum pool were comparable, ranging from 0.8 to 1.5 µg. For ELISA on the test MAPs the concentration was adjusted in every case to 150 ng/ml.

Animal immunisations

Immunising phage were prepared from XL1-blue infected cells and CsCl purified as previously described (Felici et al., 1991). Three to five weeks old female BALB/C mice (Charles River, Como, Italy) were immunised by intraperitoneal injection of 100µl of antigen solution at day 0, 21 and 42 and bled at day 52 (third bleed) and day 148 (fourth bleed). Phage were injected as 0.9% NaCl suspensions at a concentration of about 0.3 mg/ml (2.5×10^{13} phage particles/ml) without added adjuvant.

For peptide immunisations, MAPs were dissolved in PBS at a final total concentration of 400 µg/ml and injected as a 1:2 dilution in either Complete Freund's Adjuvant (first injection) or Incomplete Freund's Adjuvant (booster injections). Four to seven weeks old female Balb/c mice (Charles River, Como, Italy) were immunised by i.p. injection of 100 µl of antigen solution at weeks 0, 3 and 6 and bled at days 0 (pre-bleed) and 10 days after each additional injection. When more than one peptide were used for the immunization, equal amounts of each mimotope were mixed, and 100 µl of a 400 µg/ml solution was used.

EXAMPLE 6 - Immunogenic properties of peptides and E2 recombinant proteins. DNA immunisation in vivo.

Immunogenic properties of some of the selected HVR1 mimotopes were explored either alone or as N-terminal fusion to the ectodomain of the E2 protein

The hcv E2 peptide is generally identified by the peptide spanning from amino acid 384 to amino acid 809 of the HCV polyprotein. The HVR1 region is generally identified as amino acid 384 to 410. In the following examples ΔE2 identifies peptides corresponding to aa411 to aa683 of the HCV polyprotein.

Construction of recombinant plasmids

5   Three types of plasmids were produced and their structure is

reported in Figure 9:

(i) pΔE2 - directing the synthesis of an E2 protein fragment

(HCV strain N, Nishihara et al.; Gene; 1993; 129 pp 207-214;

from aa411 to aa683 of the HCV polyprotein) carrying a

10   deletion of both the HVR1 and the C-terminal hydrophobic

region;

(ii) a second plasmid pF78 expressing one of the HVR1

mimotopes;

(iii) a set of 11 constructs (pMimoE2) in which DNA sequences

15   encoding for the eleven different HVR1 mimotopes were fused at

the 5' end of the ΔE2 coding sequence in the plasmid pΔE2.

All recombinants were cloned in frame downstream of the tissue

plasminogen activator (TPA) signal sequence to enforce

secretion of the antigen.

20

ΔE2 gene (therefore coding for the peptides spanning from aa

411 to aa 683) was cloned using as PCR template an E2 N strain

containing vector (Nishihara et al.; Gene; 1993; 129 pp 207-

214). A PCR fragment was obtained using synthetic

25   oligonucleotide primers :(oligo fwd =

GCGAGATCTTAATTAACGATATCCAGCTTATAAAC (SEQ ID NO: 193);

oligo rev = TCCGGATCCTTAGTGGTGGTGGTGGTGGTGCGGTAG (SEQ ID NO: 194)).

By the use of these primers the resulting PCR product

5   comprises, besides the ΔE2 gene, BglII, PacI and EcoRV

restriction sites at the 5' end, and a sequence coding for six

histidine residues (His tag), and a TAA termination codon

followed by BamHI restriction site at the 3' end. This PCR

product is than digested with BglII and BamHI and ligated at

10   the BglII site of V1JnsTPA vector (J.J. Donnelly et al. The

Journal of Infect. Diseases; 1996; 713; pp314-320) in frame

with TPA leader sequence to obtain the plasmid V1JnsTPA-ΔE2

(designated pΔE2 in Figure 9).

15   HVR1 mimotope sequences were subcloned at the 5' end of ΔE2

gene in pΔE2. HVR1 fragments were PCR-amplified directly from

selected phage supernatant. The 5' primer contained PacI

restriction site and was complementary to a 5' sequence

(GGCGGCCGTTTAATTAAC; SEQ ID NO: 195) which is a constant part

20   of HVR1 mimotope sequences; the 3' primers were complementary

to the last 15 nucleotides and were different according to the

mimotope sequence cloned. PCR-amplified fragments were PacI

digested and ligated into pΔE2 plasmid. A total number of 11

pMimoE2 (Figure 9) plasmids were generated.

25

Furthermore a pF78 (Figure 9) pasmid was constructed by PCR

amplification of F78 sequence

(oligo fwd = GCGAGATCTTAATTAACCAGACCCATACCACC (SEQ ID NO:

196); oligo rev =

5   TCCGGATCCTTAGTGGTGGTGGTGGTGGTGGTTCTGTTTCGCGCC (SEQ ID NO:

197)) and cloning at the BglII site of V1JnsTPA vector.

Large-scale DNA preparations were performed using Qiagen 2500-

Tip columns, following manufacturer's instructions (Qiagen,

Hilden, Germany).

10

Characterisation of mimotope/E2 recombinant proteins

The ability of pF78, pΔE2 and pMimoE2 plasmids to drive the

expression of recombinant proteins in a mammalian system was

15 assessed by transient transfection of 293 cells. pΔE2.and

pMimoE2 transfected cells showed a strong and specific

staining when probed with an anti-E2 monoclonal antibody (mAb-

185) recognising an epitope located downstream of the HVR1.

Also mF78 expression was demonstrated by immunocytochemistry

20 of transfected 293 cells using a mice antiserum obtained by

immunisation with a MAP reproducing the amino acid sequence of

mimotope F78. These data were confirmed by ELISA on whole

cell extracts from transfected cells. Significant amounts of

all recombinant proteins were also secreted in the medium as

25 measured by ELISA on cell culture supernatants from

transfected cells.

Both intracellular and secreted proteins were heterogeneously glycosylated as suggested by their appearance as a cluster of slow migrating bands in SDS PAGE. The higher molecular weight displayed by the extracellular protein fraction is indicative of a different extent of glycosylation and confirms that the protein is actively secreted and not simply released by lysed cells. In both cases, endoglycosydase treatment leads to an increase of the migration rate to the one expected from the amino acid composition.

All recombinant mimotope/E2 fusion proteins as well as the ΔE2 mutant were efficiently recognised by two different conformation-sensitive monoclonal antibodies. Furthermore, no cysteine-bridged multimeric aggregate was visible by Western blot on non reducing SDS PAGE of either the cellular or the secreted fraction from each clone. Similar results were obtained by transfecting mouse rabdomyosarcoma cells thereby providing indication that efficient expression will be achieved upon *in vivo* transfection of mouse muscle cells.

Plasmid DNA immunisation

Four weeks old female Balb/c mice (Charles River, Como, Italy) were used for immunisations. Fully anaesthetised mice

80

received from 100 μg of plasmid DNA dissolved in 100 μl of saline buffer (PBS). Fifty microliters of DNA were injected bilaterally into quadriceps muscle via insulin syringe (B-D, U-100 28G1/2 microfine needle). Mice were given three or four injections at 3-weeks intervals and were bled two weeks after each injection. Sera were analysed for antibody titre and cross-reactivity.

Serology of αΔE2 and α HVR1 antibodies

ELISA 96 well plates (Immunoplate Maxisorp; Nunc, Roskilde, Denmark) were coated with 1 μg/well GNA (Sigma L8275) in 50 mM NaHCO$_3$ at pH 9.6 and incubated overnight at 4°C. Plates were washed (PBS/0.1% Tween 20) and incubated 1 hr at 37°C with 250 μl/well of blocking buffer (2% BSA, 1X PBS, 0.1% Tween 20). F78E2 or ΔE2 proteins were produced by transient transfection in 293 cells. 10X concentrated supernatant were used as target antigen in ELISA. Saturating amount of each protein/well were incubated in blocking buffer 3 hrs at RT on GNA-coated plates. Serial dilutions of immune sera (from 1:100 to 1:72900) were pre-incubated for 2 hrs at RT with 1 μl/well of 10X supernatant from mock transfected 293 cells in blocking buffer. Sera incubation was performed o/n at 4°C. After 1 hr at RT of IIAb incubation (α-mouse IgG Fc-specific AP conjugated, SIGMA 7434, diluted 1:2000 in blocking buffer),

plates were developed for 30 minutes at 37°C.

Anti HVR1 mimotope antibodies were titrated (dilutions of sera from 1:100 to 1:72900) by ELISA assay using for each

5   serum the homologous peptide sequence in the form of MAP.

In all cases sera titre was defined as the highest serum dilution that resulted in an absorbance value of 0.3 O.D. (almost 6 times the background value).

10

Cross-reactivity assay

Sera were assayed for their cross-reactivity to different HVR1 natural variants using a set of 43 representative MAPS as

15   described in Materials and Methods.

Intramuscular injection of mimotope encoding constructs induces a strong humoral response

20   Plasmids pΔE2 and pF78E2 were used to set up the optimal conditions for induction of humoral response. Induction of antibodies against epitopes located outside of the HVR1 was monitored by ELISA using the ΔE2 protein expressed by transiently transfected 293 cells. Balb/C and C57black mice

25   were immunised to test the immunogenicity of the mimotope

82

the number of injections (from one to four) and the amount of

injected DNA directly correlated with the magnitude of

antibody response. The highest antibody titres against the

ΔE2 protein were obtained after three injections at three

5   weeks-intervals using fifty or one hundred micrograms of pΔE2

DNA per mouse. Further injections did not improve titres. A

similar kinetic of induction of antibodies against the ΔE2

protein was observed following mice immunisation with plasmid

pF78E2. Induction of anti-HVR1 antibodies in this latter

10   group of animals was tested by ELISA on MAPF78. No

significant difference was observed between the two strains of

mice under investigation as far as the optimal conditions of

immunisation are concerned, but C57black mice showed on

average better responses.

15

Antisera from mice immunised with the construct expressing

only the F78 HVR1 mimotope (pF78) also induced a specific

response, but the titres were much lower than those obtained

by using the related pF78E2 construct. Several factors such

20   as the level of expression, the folding of the recombinant

products or the presence of stronger T helper epitopes might

be responsible for the higher response observed with the

fusion constructs as compared to the F78 mimotope alone.

25

Anti-mimotope sera cross-react with different natural HVR1 variants

The ability of mimotope/E2 fusions to elicit a cross-reactive
5 response by DNA-based immunisation, was evaluated using a
panel of forty-three synthetic peptides reproducing the HVR1
sequences of natural isolates as coated antigens in ELISA (see
Materials and methods).

In Table III are reported the average titres obtained by
immunisation of Balb/c mice (upper panel) and C57Black mice
(lower panel) using different individual plasmids or mixtures
of plasmids. Crossreactivity is reported as number of
5 peptides scored as positive of the 43 tested.

pB14E2 and pB24E2 plasmids did not induce a cross-reactive
immune response, in spite of the presence of significant
levels of antibodies specific for a peptide displaying the
10 homologous mimotope sequence in the relative immune sera
(Table III). All the other constructs gave rise to anti-sera
cross-reacting against some of the natural HVR1 sequences,
with the anti-F78 sera being able to recognise up to 28% of
the tested peptides (Table III).

15

The extent of cross-reactivity of the immune sera generally
reflected the immunogenicity of the individual plasmids as, in
most cases, a higher titre corresponded to a higher level of
cross-reactivity (Table III). Nevertheless, titre alone
20 cannot always explain the differences in cross-reactivity, as
shown with sera from mice immunised with plasmid pR6E2 which
induced lower titres than the pD6E2, pH1E2 and pM63E2
. constructs, but reacted with a larger number of natural HVR1
peptides. Similarly, sera from mice immunised with the pF7E2,
25 pM122E2 and pR9E2 showed a cross-reactivity two fold higher
than that observed with the pG31E2 immune sera, despite

85

similar titres (Table III).

In C57Black mice injection of the pF78E2 chimaeric gene led to
the development of a stronger response with a consequently
higher cross-reactivity as compared to Balb/C mice (49% vs
28%).

*Immunisation with mixtures of plasmids improves the cross-
reactivity of the response*

Three groups of Balb/C mice were immunised with mixtures of
plasmids encoding for mimotope/E2 chimaeras, each mouse
receiving a total amount of 100 μg DNA/injection.

Mixture A contained the plasmids encoding for D6, F78, G31,
H1, M122 and R6 fusions to E2. Mixture B also included the
other three constructs that induced cross-reactive antibodies:
pE19E2, pM63E2 and pR9E2, while Mixture C comprised all eleven
plasmids. (Mixtures of peptides, and nucleic acid encoding
peptides, according to each of Mixture A, Mixture B and
Mixture C represent further aspects of the present invention.)

All three mixtures were immunogenic, and induced highly cross-reactive antisera (Table III). Antibodies from animals immunised with Mixture A did not show higher cross-reactivity as compared to those obtained by injecting individual plasmids

5   included in the cocktails. However, it must be emphasised that in the former case titres were about fifty fold lower, suggesting that Mixture A has the potential to induce a more widely cross-reacting response provided efficiency of the immunisation is increased. The results obtained with Mixture

10   B lent further support to this hypothesis. Mice receiving the second mixture of plasmids showed a net increase in cross-reactivity in that they developed anti-sera able to recognise about 50% of the tested natural HVR1 sequences. Also in this case the average titres were one order of magnitude lower than

15   those displayed by the most cross-reacting sera from animals immunised with individual plasmids (Table III).

Intramuscular delivery of the most complex mixture including all plasmids encoding for the mimotope/E2 chimaeras did not

20   further improve the breath of reactivity of the resulting immune sera. This result is consistent with the observed lack of cross-reactivity displayed by the animals immunised with the two additional constructs present in this cocktail (pB14E2 and pB24E2).

25

Similar data were obtained by immunising C57black mice.

REFERENCES

Alter, H.J. (1995) Blood 85, 1681-1695.

5   Bartoli, F., *et al.*(1996) BioTechniques *20* 554-558.

Bukh, J.,1995) Seminars in Liver Disease 15, 41-63.

Casari, G., *et al.* (1995) Nature Structural Biology. 2, 171-178.

Choo, Q.L., *et al.* (1989) Science 244, 359-362.

10   Choo, Q.L., *et al.* (1994) Proc. Natl. Acad. Sci. USA 91, 1294-1298.

Cohen, J, (1993) Science *259*: 1691-1692.

Cormack, B.P. and Struhl, K. (1993). Science *262* 244-248.

Cortese, R., *et al.* (1994) Tibtech 12, 262-266.

15   Cortese, R., *et al.* (1996) Current Opinions in Biotechnology 7, 616-621.

Dente, L., *et al.* (1994) Gene *148*, 7-13.

Farci, P., *et al.* (1992) Science *258* 135-140.

Farci, P., *et al.* (1994) Proc. Natl. Acad. Sci. USA 91, 7792-

20   7796.

Farci, P., *et al.* (1996) Proc. Natl. Acad. Sci. USA 96, 15394-15399.

Felici, F.,*et al.* (1991) J. Mol. Biol. *222*, 301-310.

Folgori, A.,*et al.* (1994) EMBO J. 13, 2236-2243.

25   Fried, M.W. and Hoofnagle, J.H. (1995) Semin. Liver Dis. 15, 82-91.

Kato, N., *et al.* (1993) J. Virol. 67, 3923-3930.

Kojima, M., *et al.* (1994) Virology 204, 665-672.

Kurosaki, M., *et al.* (1994) Virology 205, 161-169.

Major, M.E., *et al.* (1995) J. Virol. 69, 5798-5805.

5 Martell, M., *et al.* (1992) J. Virol. 66, 3225-3229.

Martell, M., *et al.* (1994) J. Virol. 68, 3425-3436.

Mast, E.E. and Alter, M.J. (1993) Semi. Virol. 4, 273-283.

Mecchia, M., *et al.* (1996). J. Immunol., 157, 3727-3736.

Meola, A., *et al.* (1995). J. Immunol. 154, 3162-3172.

10 Pessi, A., *et al.* (1990). J. Chem. Soc, Chemical
Communications, 1, 8-9.

Prezzi, C., *et al.* (1996). J. Immunol. 156, 4504-4513.

Scarselli, E., *et al.* (1995) J. Virol. 69, 4407-4412.

Shimizu, Y.K., *et al.* (1992) Proc. Natl. Acad. Sci. USA 89,

15 5477-5481.

Shimizu, Y.K., *et al.* (1994) J. Virol. 65, 1494-1500.

Shimizu, Y.K., *et al.* (1997). J. Virol. 71, 5769-5773.

Silini, E., *et al.* (1995) Hepatology *21*, 285-290.

Simmonds, P., *et al.* (1993). J. Gen. Vir. 74, 2391-2399.

20 Tam, J.P. (1988) Proc. Natl. Acad. Sci. USA 85:5409-5413.

van Doorn, L., *et al.* (1995) J. Virol. 69, 773-778.

Weiner, A.J., *et al.* (1991). Virology 180, 842-848.

Weiner, A.J., *et al.* (1992). Proc.Natl.Acad. Sci.USA *89* 3468-
3472.

25 Weiner, A., *et al.* (1995). Proc. Natl. Acad. Sci. USA 92,
2755-2759.

Winter, G. and Milstein, C. (1991) Nature 349, 293-299.

Yang, N.S., *et al*.(1990). Proc. Natl. Acad. Sci. USA 87: 9568-9572.

TABLE I - Scheme of the selections.

First and second round of HVR1 library enrichment with sera
from HCV infected patients are indicated at the top of the

5 table.   Names of the sera and the genotype of the
corresponding infecting virus (in brackets) are shown in the
left column.   In the right column are indicated the names of
the resulting phage pools.

10 *TABLE II - Amino acid frequencies observed in the set of
"strong" and "weak" crossreactive mimotopes.*

i indicates amino acid position (1 to 27); aa indicates amino
acids in standard one letter code; Fs(i,aa) is the frequency

15 in position i of the amino acid aa in the "strong" mimotopes;
Fw(i,aa) is the frequency in position i of the amino acid aa
in the "weak" mimotopes.

Table I

Ist selection				IInd selection		
serum/genotype		phage pool		serum/genotype		phage pool
σ4R	(1b)	4R		σ2	(1b)	B
σ3R	(3a)	3R		σ1	(1a)	D
σ3	(2a)	3		σ2	(1b)	E
σ2R	(3a)	2R		σ3	(2a)	R
σ1	(1a)	1		σ4	(2a)	F
				σ2	(1b)	H
σ2P	(2b)	2P		σ2	(1b)	G
				σ1	(1a)	L
				σ4	(2a)	M
σN		N				

Table II

i	aa	Fs (i,aa)	Fw (i,aa)
1	Q	0.70	0.64
	T	0.30	0.36
2	T	1.00	1.00
3	H	0.52	0.28
	I	0.48	0.12
	R	0.00	0.60
4	T	0.70	0.52
	V	0.30	0.48
5	V	0.56	0.36
	T	0.44	0.64
6	G	1.00	1.00
7	G	1.00	1.00
8	Q	0.41	0.24
	S	0.30	0.56
	V	0.29	0.20
9	A	0.48	0.28
	Q	0.37	0.40
	V	0.15	0.32
10	S	0.44	0.64
	G	0.37	0.32
	A	0.19	0.04
11	H	0.82	0.40
	R	0.18	0.60
12	Q	0.52	0.44
	A	0.26	0.20
	T	0.22	0.36
13	A	0.37	0.28
	T	0.33	0.52
	V	0.30	0.20
14	S	0.48	0.32
	H	0.41	0.32
	R	0.11	0.36

i	aa	Fs (i,aa)	Fw (i,aa)
15	S	0.52	0.32
	G	0.41	0.24
	R	0.07	0.44
16	L	1.00	1.00
17	T	0.78	0.52
	V	0.22	0.48
18	S	0.48	0.24
	G	0.45	0.36
	R	0.07	0.40
19	L	1.00	1.00
20	F	1.00	1.00
21	S	1.00	0.20
	R	0.00	0.80
22	P	0.89	0.32
	L	0.07	0.28
	Q	0.04	0.32
	S	0.00	0.08
23	G	1.00	1.00
24	A	0.41	0.04
	S	0.37	0.20
	P	0.22	0.76
25	K	0.41	0.32
	S	0.41	0.36
	Q	0.18	0.32
26	Q	1.00	1.00
27	N	0.67	0.52
	K	0.33	0.48

Table III

plasmid	titre	n. positive peptides
pB14E2	270	0
pB24E2	189	0
pD6E2	4222	3
pE19E2	990	2
pF78E2	31812	12
pG31E2	31251	5
pH1E2	2977	1
pM63E2	3888	2
pM122E2	41360	10
pR6E2	1923	6
pR9E2	21092	11
mF78	110	2
MIX	684	11
MIX	1224	19
MIX	610	18

plasmid	titre	n. positive peptides
pF78E2	41547	21
MIX	20381	24